EP300 / CBP inhibitors

Novel compounds targeting EP300/CBP with specific structures provide high selectivity and inhibitory activity, addressing the clinical inadequacies of existing inhibitors by effectively treating tumors and malignant diseases.

JP7591566B2Active Publication Date: 2024-11-28HINOVA PHARM INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2022518967
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-09-27
Filing Date
2020-09-25
Publication Date
2024-11-28
Estimated Expiration
2040-09-25

AI Technical Summary

Technical Problem

Existing EP300/CBP inhibitors lack the necessary clinical efficacy and selectivity required for effective tumor therapy.

Method used

Development of novel compounds with specific structures, represented by formulas I, I', II, II', III, and IV, which exhibit high selectivity and inhibitory activity against EP300/CBP, targeting various tumor cells including prostate cancer, leukemia, and multiple myeloma.

Benefits of technology

The compounds demonstrate high selectivity for EP300/CBP, effectively inhibiting their activity and showing excellent inhibitory effects on tumor cells, offering potential therapeutic benefits for tumors and malignant diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591566000001
    Figure 0007591566000001
  • Figure 0007591566000002
    Figure 0007591566000002
  • Figure 0007591566000003
    Figure 0007591566000003
Patent Text Reader

Abstract

The present invention provides an EP300 / CBP inhibitor, specifically a compound represented by Formula I, or a deuterated derivative thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof. The compound has high selectivity for EP300 / CBP and can effectively inhibit the activity of EP300 / CBP. Furthermore, the compound has excellent inhibitory effects on various tumor cells, including prostate cancer cells, leukemia cells, breast cancer cells, and multiple myeloma cells. The compound has potential applications in the manufacture of EP300 / CBP inhibitors and drugs for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem / progenitor cells, and regulating regulatory T cells. TIFF2022549471000361.tif2839
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention belongs to the field of drug synthesis, and specifically relates to EP300 / CBP inhibitors with novel structures and the use of said EP300 / CBP inhibitors in pharmaceuticals. [Background technology]

[0002] Histone acetyltransferases (HATs) and histone deacetylases (HDACs) can affect the acetylation of histones; recruitment of HATs and HDACs for normal function is a key regulatory step in gene expression and the cell cycle; functional defects of these enzymes can lead to various diseases, including tumors.

[0003] The EP300 / CBP family, consisting of the highly homologous adenovirus E1A-associated 300 kDa protein (EP300) and cyclic AMP-responsive element-binding protein (CREB)-binding protein (CBP), is one of the major members of the histone acetyltransferase (HAT) family. Studies have shown that EP300 and CBP bind to chromatin via their bromodomains (BRDs) and are very important coactivators involved in cell cycle progression and cell growth, differentiation, and proliferation, and can regulate the functions of several key transcription factors. Studies have also shown that EP300 / CBP is highly expressed and activated in various tumors and is closely associated with various tumor diseases, making it a very promising target for tumor therapy. Therefore, EP300 / CBP inhibitors have attracted increasing attention among researchers.

[0004] Zhou's group and Hewings' group have disclosed representative EP300 / CBP inhibitors with micromolar affinity as shown below in 1a, 2a, and 3a. CBP in 1a has a Kd of 19.6 μmol.L.-1 , CBP of 2a has Kd=19μmol.L -1 , CBP of 3a has IC50 = 28.1 μmol.L -1 ). JPEG0007591566000001.jpg39144

[0005] Researchers at the Structural Genomics Consortium (SGC) at the University of Oxford first designed and synthesized a benzimidazole compound, 9a, but it showed poor selectivity for CBP and BRD4 (CBP: IC50 = 4 μmol L -1 ,BRD4: IC50=6.3μmol L -1 After further optimization, compound 10a (CBP: IC50 = 0.12 μmol L -1 ,BRD4: IC50=2.4μmol L -1 ) and 11a (SGC-CBP30, CBP: IC50 = 69 nmol.L -1 ,Kd=21nmol.L -1 , p300: Kd=32nmol.L -1 ) was obtained. JPEG0007591566000002.jpg40147

[0006] However, the EP300 / CBP inhibitors reported so far have yet to meet clinical needs, so it is of great significance to further research EP300 / CBP inhibitors with new structures, higher selectivity and superior inhibitory activity. Summary of the Invention

[0007] An object of the present invention is to provide a highly active EP300 / CBP inhibitor having a new structure.

[0008] The present invention provides a compound of formula I, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, TIFF0007591566000003.tif2330 Wherein R1 is selected from a 5-6 membered saturated or unsaturated cycloalkyl group substituted with 0-4 R7, a 5-6 membered saturated or unsaturated heterocyclyl group substituted with 0-4 R7, and each R7 is independently selected from C 1~5 Alkyl group or its deuterated derivative, =O, C 1~5 is selected from an alkoxy group or its deuterated derivative, a halogen, a hydroxy group, and a cyano group; R2 is selected from a 5- to 6-membered saturated cycloalkyl group substituted with 0-4 R5, and a 5- to 6-membered saturated heterocyclyl group substituted with 0-4 R5, each R5 being independently selected from C 1~5 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, =O, C 1~5 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, cyano groups, Selected from TIFF0007591566000004.tif1414, R6 is C 1~5 is an alkyl group, R3 is selected from a 3- to 7-membered saturated or unsaturated cycloalkyl group substituted with 0 to 4 R4, and a 3- to 7-membered saturated or unsaturated heterocyclyl group substituted with 0 to 4 R4, each R4 being independently =O, =S, SO2, a cyano group, C 1~5 Alkyl group or its deuterated derivative, C 1~5 Alkoxy groups or their deuterated derivatives, hydroxy groups, halogens, TIFF0007591566000005.tif1722, or two R4 are linked to form a 3- to 4-membered ring, where R8 is C 1~3 An alkyl group or a halogen, and n is an integer of 0-4.

[0009] Further, R1 is selected from a 5-6 membered saturated or unsaturated cycloalkyl group substituted with 1-3 R7, a 5-6 membered saturated or unsaturated heterocyclyl group substituted with 1-3 R7, wherein the heteroatoms on the heterocyclyl group are selected from O, N, and S, and each R7 is independently selected from C 1~3 is selected from an alkyl group or its deuterated form, =O; R2 is selected from a 5-6 membered saturated cycloalkyl group substituted with 1-3 R5, a 5-6 membered saturated heterocyclyl group substituted with 1-3 R5, the heteroatoms on the heterocyclyl group being selected from O, N, and S, and each R5 is independently selected from C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, =O, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, cyano groups, Selected from TIFF0007591566000006.tif1414, R6 is C 1~3 is alkyl, R3 is selected from a 3- to 7-membered saturated or unsaturated cycloalkyl group substituted with 0 to 4 R4, and a 3- to 7-membered saturated or unsaturated heterocyclyl group substituted with 0 to 4 R4, and the heteroatoms on the heterocyclyl group are selected from one or more of O, S, and N, and each R4 is independently =O, =S, SO2, a cyano group, C 1~3 Alkyl group or its deuterated derivative, C 1~3 Alkoxy groups or their deuterated derivatives, hydroxy groups, halogens, TIFF0007591566000007.tif1621, or two R4 are linked to form a 3- to 4-membered saturated carbocycle or a 3- to 4-membered saturated heterocycle, where R8 is a halogen and n is an integer of 1 to 3.

[0010] Furthermore, the structure of the compound is as shown in formula II-1: TIFF0007591566000008.tif3832R5 is C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 is selected from an alkoxy group or its deuterated derivative, a halogen, and a hydroxy group, and m is 1 or 2; R1 and R3 are as described above. Or, the structure of the compound is as shown in formula II-2: TIFF0007591566000009.tif3832R5 is C 1~3Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, Selected from TIFF0007591566000010.tif1414, R6 is C 1~3 is an alkyl group, R1 and R3 are as described above. Or, the structure of the compound is as shown in formula II-3: TIFF0007591566000011.tif3335R5 is C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, Selected from TIFF0007591566000012.tif1414, R6 is C 1~3 is an alkyl group, R1 and R3 are as described above. Or, the structure of the compound is as shown in formula II-4: TIFF0007591566000013.tif3733R1, R3 are as above.

[0011] Furthermore, R1 is JPEG0007591566000014.jpg2524, JPEG0007591566000015.jpg2329, JPEG0007591566000016.jpg2228, JPEG0007591566000017.jpg2427, Selected from JPEG0007591566000018.jpg2124, and / or R3 is JPEG0007591566000019.jpg1919, TIFF0007591566000020.tif1915, TIFF0007591566000021.tif1719, JPEG0007591566000022.jpg2023, JPEG0007591566000023.jpg2221, JPEG0007591566000024.jpg1921, JPEG0007591566000025.jpg2120, JPEG0007591566000026.jpg1821, JPEG0007591566000027.jpg2121, JPEG0007591566000028.jpg2021, JPEG0007591566000029.jpg2020, JPEG0007591566000030.jpg1823, JPEG0007591566000031.jpg2025, JPEG0007591566000032.jpg2021, JPEG0007591566000033.jpg1724, TIFF0007591566000034.tif1718, TIFF0007591566000035.tif1915, TIFF0007591566000036.tif1714, TIFF0007591566000037.tif1916, TIFF0007591566000038.tif1914, JPEG0007591566000039.jpg2022, JPEG0007591566000040.jpg1822, JPEG0007591566000041.jpg2122, JPEG0007591566000042.jpg2222, TIFF0007591566000043.tif1819, Selected from TIFF0007591566000044.tif2020, where R4 is JPEG0007591566000045.jpg2114, JPEG0007591566000046.jpg2516, JPEG0007591566000047.jpg2321, TIFF0007591566000048.tif2316, TIFF0007591566000049.tif2216, and R9 is selected from an alkyl group or a haloalkyl group.

[0012] Furthermore, the compound is one of the following compounds: TIFF0007591566000050.tif39154 TIFF0007591566000051.tif86164

[0013] The present invention further provides a compound of formula I', or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, JPEG0007591566000052.jpg6066In this case, R1' is a substituted or unsubstituted 5- to 6-membered saturated or unsaturated cycloalkyl group, a substituted or unsubstituted 5- to 6-membered saturated or unsaturated heterocyclyl group, a substituted or unsubstituted C 1~5 Alkyl groups, substituted or unsubstituted C 2~6 R is selected from an olefin, a substituted or unsubstituted amino group, a substituted or unsubstituted amide group, a substituted or unsubstituted carboxylate group, a substituted or unsubstituted urea group, a substituted or unsubstituted halogen, a substituted or unsubstituted hydroxy group, and a substituted or unsubstituted cyano group, wherein the substituents on R are one or more and each of the substituents is independently selected from deuterium, deuterated or non-deuterated C 1~4 Alkyl groups, deuterated or non-deuterated C 1~4 Alkoxy groups, cycloalkyl groups, heterocyclyl groups, CONR 2a R 2b , COOR 2c , C.O.R. 2d , COL1NR 2f R 2g , SO2R 2e, =O, =S; R 2a , R 2b , R 2c , R 2d , R 2e , R 2f , R 2g each independently represents a halogenated or non-halogenated C 1~4 alkyl group, L1 is absent or C 1~2 alkylene groups, L0 is absent or C 1~2 alkylene groups, Ring A is a 5- to 7-membered saturated or unsaturated cycloalkyl group or a 5- to 7-membered saturated or unsaturated heterocyclyl group substituted with 0, 1 or more R3', where each R3' is independently deuterium, =O, =S, C 1~4 Alkyl group, C 1~4 Alkoxy group, cyano group, 0 to 4 R 3a an aryl group substituted with 0 to 4 R 3a or two R' are linked together to form a ring, and R 3a are each independently a halogen, an amino protecting group, C 1~4 Alkyl group, C 1~4 an alkoxy group, a cyano group; n1 is an integer from 0 to 2, and n2 is an integer from 0 to 2, X is CH, N, O or S; R x is absent, hydrogen, deuterium, deuterated or non-deuterated C 1~4 Alkyl groups, deuterated or non-deuterated C 1~4 Alkoxy group, COR x1 Selected from R x1 is deuterated or non-deuterated C 1~3 It is an alkyl group.

[0014] Furthermore, the structure of the compound is as shown in formula II': JPEG0007591566000053.jpg6772, where R 1a , R 1b each independently represents hydrogen, deuterium, deuterated or non-deuterated C1~3 Alkyl groups, deuterated or non-deuterated C 1~3 alkoxy groups, L0 is selected from absence or a methylene group; Ring A is a 5- to 7-membered saturated or unsaturated cycloalkyl group or a 5- to 7-membered saturated or unsaturated heterocyclyl group substituted with 0, 1 or more R3', where each R3' is independently deuterium, =O, =S, C 1~4 Alkyl group, C 1~4 Alkoxy group, cyano group, 0 to 4 R 3a an aryl group substituted with 0 to 4 R 3a or two R' are linked together to form a ring, and R 3a are each independently a halogen, an amino protecting group, C 1~4 Alkyl group, C 1~4 an alkoxy group, a cyano group; n1 is 0 or 1, n2 is 0 or 1, X is CH, N, O or S; R x is absent, hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 Alkoxy group, COR x1 Selected from R x1 is deuterated or non-deuterated C 1~2 is an alkyl group, The salts are pharma- ceutically acceptable salts.

[0015] Furthermore, the structure of the compound is as shown in formula III-1 or formula III-2: TIFF0007591566000054.tif6272 TIFF0007591566000055.tif6273 where R 1a , R 1b each independently represents hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 alkoxy groups, n1 is 0 or 1, preferably 1; n2 is 0 or 1, preferably 1; m1 is 0 or 1, m2 is 0 or 1, preferably 1; Y1 is O or S; Y2 is O, S, CR Y1 R Y2 , N.R. Y3 and R Y1 , R Y2 , R Y3 are independently hydrogen, deuterium, and C 1~3 Alkyl group, C 1~3 alkoxy groups, R x is hydrogen, deuterium, deuterated or non-deuterated C 1~2 Alkyl groups, deuterated or non-deuterated C 1~2 Alkoxy group, COR x1 Selected from R x1 is deuterated or non-deuterated C 1~2 is an alkyl group, R3' is 0 to 3 R 3a A phenyl group or a heteroaryl group substituted with R 3a is a phenyl group substituted with R 3a is a halogen, said halogen being preferably fluorine, chlorine or bromine.

[0016] Furthermore, the structure of the compound represented by formula III-1 is as represented by formula III-3, TIFF0007591566000056.tif7673 where R 1a , R 1b each independently represents hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 alkoxy groups, R x is hydrogen, deuterium, deuterated or non-deuterated C 1~2 Alkyl groups, deuterated or non-deuterated C 1~2 alkoxy groups, n3 is 2 or 3, preferably 2; R3 is a halogen, said halogen being preferably fluorine, chlorine or bromine.

[0017] Further, the structure of the compound is as shown in Formula IV: TIFF0007591566000057.tif6373 where R 1a , R 1b each independently represents hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 alkoxy groups, n1 is 0 or 1, preferably 1; n2 is 0 or 1, preferably 1; R x is absent, hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 Alkoxy group, COR x1 Selected from R x1 is deuterated or non-deuterated C 1~2 is an alkyl group, Y3 is CH or N; m3 is an integer of 0 to 3, preferably 2 or 3; R4 is independently a cyano group, C 1~3 Alkyl group, C 1~3 alkoxy groups, and substituted or unsubstituted phenyl groups, the substituents on the phenyl groups being selected from halogen, C 1~3 Alkyl group or C 1~3 The alkoxy group is selected from the group consisting of aryl, ... and aryl groups.

[0018] Furthermore, the compound is one selected from the following compounds: TIFF0007591566000058.tif33169 TIFF0007591566000059.tif32169 TIFF0007591566000060.tif81149 TIFF0007591566000061.tif40169 TIFF0007591566000062.tif41141 TIFF0007591566000063.tif88169 TIFF0007591566000064.tif48131 TIFF0007591566000065.tif35169 TIFF0007591566000066.tif34169 TIFF0007591566000067.tif36140 TIFF0007591566000068.tif37169 TIFF0007591566000069.tif77170

[0019] The present invention further provides the use of the above-mentioned compound, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystal form thereof, or a solvate thereof, in the manufacture of an EP300 inhibitor, a CBP inhibitor, or an EP300 / CBP inhibitor.

[0020] Furthermore, the EP300 / CBP inhibitor is a drug for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem / progenitor cells, and regulating regulatory T cells; Preferably, the tumor is selected from hematological malignancies, gastric cancer, intestinal cancer, cervical cancer, bladder cancer, laryngeal cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma or multiple myeloma, and the malignant disease of myeloid hematopoietic stem / progenitor cells is leukemia; More preferably, the lymphoma is non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and the leukemia is acute myeloid leukemia.

[0021] The present invention further provides a drug for treating a disease, which is a formulation produced by adding pharmaceutically acceptable auxiliary materials to the above-mentioned compound, or a deuterated product thereof, or a salt thereof, or a conformer thereof, or a crystal form thereof, or a solvate thereof, as an active ingredient.

[0022] The present invention further provides a combination drug containing the above-mentioned compound, or a deuterated product thereof, or a salt thereof, or a conformer thereof, or a crystal form thereof, or a solvate thereof, and another drug having an antitumor activity, and a pharma- ceutically acceptable carrier, which are used for simultaneous or separate administration in unit dosage forms of the same or different specifications.

[0023] Furthermore, said other drug having an antitumor effect is a chemotherapy drug or a radiotherapy drug, preferably said chemotherapy drug is a targeted drug.

[0024] Furthermore, the other drug having an antitumor effect is one or more selected from a CDK4 / 6 inhibitor, a PARP inhibitor, an androgen receptor inhibitor, and an immune checkpoint inhibitor, and the CDK4 / 6 inhibitor is preferably palbociclib.

[0025] The definitions of terms used in the present invention are as follows: Unless otherwise specified, the initial definition provided by a group, radical or term in the text applies to the group or term throughout the entire specification, and any term not specifically defined in the text shall represent the meaning that a person skilled in the art may have based on the disclosure and context.

[0026] The term "EP300 / CBP inhibitor" refers to an inhibitor that can simultaneously inhibit the activities of EP300 and CBP.

[0027] "EP300" is the same as "P300," and "EP300 / CBP inhibitor" is the same as "P300 / CBP inhibitor."

[0028] The minimum and maximum carbon atom content in the hydrocarbon group are represented by prefixes. For example, the prefix C a~b The alkyl group represents an alkyl group containing any number of carbon atoms, from "a" to "b". For example, C 1~5 Alkyl group means a straight or branched chain alkyl group containing 1 to 5 carbon atoms.

[0029] Similarly, C 1~5 An alkoxy group refers to a straight or branched chain alkoxy group containing 1 to 5 carbon atoms.

[0030] As used herein, "substituted" means that one, two or more hydrogen atoms in a molecule have been replaced with other, different atoms or molecules, including one, two or more substitutions on isotopes or isomers in the molecule.

[0031] The cycloalkyl group refers to a saturated or unsaturated cyclic hydrocarbon substituent, and the cyclic hydrocarbon may be monocyclic or polycyclic. For example, a "5- to 6-membered saturated or unsaturated cycloalkyl group" refers to a saturated or unsaturated cycloalkyl group having 5 to 6 ring carbon atoms.

[0032] A heterocyclyl group refers to a saturated or unsaturated cyclic hydrocarbon substituent that may be monocyclic or polycyclic and has at least one ring heteroatom, including but not limited to O, S, or N. For example, a "5- to 6-membered saturated or unsaturated heterocyclyl group" refers to a saturated or unsaturated heterocyclyl group having 5 to 6 ring atoms.

[0033] By aryl group is meant an all-carbon monocyclic or fused polycyclic (i.e., rings sharing adjacent pairs of carbon atoms) group having a conjugated pi-electron system, such as, for example, phenyl or naphthyl groups. The rings of said aryl groups may be fused to other cyclic groups (including saturated and unsaturated rings), but cannot contain heteroatoms such as nitrogen, oxygen, or sulfur, and at the same time, the point of attachment to the parent must be on a carbon atom in the ring having a conjugated pi-electron system. Aryl groups may be substituted or unsubstituted.

[0034] The heteroaryl group means a heteroaromatic group containing one or more heteroatoms. The heteroatoms referred to here are oxygen, sulfur and nitrogen. For example, the heteroaryl group includes a furyl group, a thienyl group, a pyridyl group, a pyrazolyl group, a pyrrolyl group, an N-alkylpyrrolyl group, a pyrimidinyl group, a pyrazinyl group, an imidazolyl group, a tetrazolyl group, and the like. The ring of the heteroaryl group may be condensed with the ring of an aryl group, a heterocyclyl group, or a cycloalkyl group, and the ring bonded to the parent structure is the ring of the heteroaryl group. The heteroaryl group may be optionally substituted or unsubstituted.

[0035] By "pharmaceutical acceptable" is meant that the carrier, vehicle, diluent, auxiliary material and / or salt formed is chemically or physically compatible with the other ingredients that normally make up the drug dosage form and physiologically compatible with the receptor.

[0036] "Salt" refers to acid and / or base salts formed by a compound or its stereoisomer with inorganic and / or organic acids and / or bases, including zwitterionic salts (internal salts) and further including quaternary ammonium salts, such as alkylammonium salts. These salts may be obtained directly in the final isolation and purification of the compound. They may also be obtained by mixing the compound or its stereoisomer with a certain amount of acid or base appropriately (e.g., equal equivalents). These salts may also be obtained by forming a precipitate in a solution and collecting it by filtration, or by recovering it after evaporation of the solvent, or by reacting in an aqueous medium and then lyophilizing it.

[0037] The salts described in this invention may be the hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, butanedioate, oxalate, malate, succinate, fumarate, maleate, tartrate, or trifluoroacetate salts of the compounds.

[0038] "Solvate thereof" means that the compound of the present invention forms a solvate with a solvent, and the solvent includes, but is not limited to, water, ethanol, methanol, isopropanol, propylene glycol, tetrahydrofuran, and dichloromethane.

[0039] The term "deuterated compound thereof" refers to a compound of the present invention in which one or more hydrogen atoms have been replaced with deuterium.

[0040] In the compound of the present invention represented by formula I', "L0 is absent or C 1~2 "Alkylene group" means that L is absent or C 1~2 where L0 is absent, the structure of the compound of formula I' is The image is JPEG0007591566000070.jpg4354.

[0041] Experimental results show that the compounds provided by the present invention have high selectivity to EP300 / CBP and can effectively inhibit the activity of EP300 / CBP.In addition, the compounds of the present invention have excellent inhibitory effects on various tumor cells, including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells.Therefore, the compounds of the present invention have potential applications in the manufacture of EP300 / CBP inhibitors and drugs for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem / progenitor cells, and regulating regulatory T cells.

[0042] In addition, the compounds of the present invention are very promising because they can be used in combination with other antitumor drugs (e.g., CDK4 / 6 inhibitors) to produce combination drugs for the prevention and / or treatment of tumors.

[0043] Naturally, based on the above content of the present invention, various other forms of modifications, substitutions or changes can be made in light of general technical knowledge and conventional means in this field, on the premise that they do not deviate from the above basic technical idea of ​​the present invention.

[0044] The above content of the present invention will be described in more detail below by specific embodiments in the form of examples. However, this should not be understood as limiting the scope of the above subject matter of the present invention. Any technology realized based on the above content of the present invention belongs to the scope of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] All the materials and equipment used in the present invention are conventional and purchased from commercial sources.

[0046] The following is a method for synthesizing the intermediate compound.

[0047] 1. Synthesis of intermediate 4-bromo-N-((trans)-4-methoxycyclohexyl)-2-nitroaniline (intermediate 1): TIFF0007591566000071.tif3896

[0048] 4-Bromo-1-fluoro-2-nitrobenzene (3.38 g, 15.4 mmol), (trans)-4-methoxycyclohexyl-1-amine (2 g, 15.4 mmol) and potassium carbonate (5.34 g, 38.6 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, 200 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 4.5 g of a solid (Intermediate 1). Yield 88.9%.

[0049] 2. Synthesis of intermediate 4-bromoN1-((trans)-4-methoxycyclohexyl)benzene-1,2-diamine (intermediate 2): TIFF0007591566000072.tif4188

[0050] Intermediate 1 (4.5 g, 13.7 mmol) and aqueous ammonia (10 mL) were dissolved in 150 mL of tetrahydrofuran and 150 mL of water, sodium dithionite (38 g, 185 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by leaving the mixture to stand, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 3.5 g of a solid (Intermediate 2). Yield: 85.6%.

[0051] 3. Synthesis of intermediate 4-(3,5-dimethylisoxazol-4-yl)-N1-((trans)-4-methoxycyclohexyl)benzene-1,2-diamine (intermediate 3): TIFF0007591566000073.tif41120

[0052] Intermediate 2 (3.5g, 11.7mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.87g, 12.8mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (80mg, 0.12mmol), potassium carbonate (3.23g, 23.4mmol) were dissolved in 60mL of dioxane and 10mL of water, purged with nitrogen gas three times, and stirred at 100°C for 10 hours. After cooling, the mixture was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 2.5g of a solid (intermediate 3). Yield 68%.

[0053] 4. Synthesis of intermediate 4-bromo-N-((trans)-4-hydroxycyclohexyl)-2-nitroaniline (intermediate 4): TIFF0007591566000074.tif38104

[0054] 4-Bromo-1-fluoro-2-nitrobenzene (3.38 g, 15.4 mmol), (trans)-4-hydroxycyclohexyl-1-amine (1.77 g, 15.4 mmol) and potassium carbonate (5.34 g, 38.6 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, 200 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 4.1 g of a solid (Intermediate 4). Yield 84.9%.

[0055] 5. Synthesis of intermediate 4-bromo-N-(((trans)-4-(methoxy-d3)cyclohexylq)-2-nitroaniline (intermediate 5): TIFF0007591566000075.tif4283

[0056] Intermediate 4 (4g, 12.7mmol) and sodium hydride (0.6g, 25.4mmol) were dissolved in 40mL of tetrahydrofuran, and deuterated iodomethane (2.8g, 19mmol) was added dropwise under ice bath and reacted overnight. The mixture was poured into ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 2.8g of product (Intermediate 5). Yield 66%.

[0057] 6. Synthesis of intermediate 4-bromoN1-((trans)-4-(methoxy-d3)cyclohexyl)benzene-1,2-diamine (intermediate 6): TIFF0007591566000076.tif4298

[0058] Intermediate 5 (4.5 g, 13.7 mmol) and aqueous ammonia (10 mL) were dissolved in 150 mL of tetrahydrofuran and 150 mL of water, and sodium dithionite (38 g, 185 mmol) was added and stirred at room temperature overnight. The organic layer was separated by standing, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 3.4 g of a solid (intermediate 6). Yield 83%.

[0059] 7. Synthesis of intermediate 4-(3,5-dimethylisoxazol-4-yl)-N1-((trans)-4-(methoxy-d3)cyclohexyl)benzene-1,2-diamine (intermediate 7): TIFF0007591566000077.tif43129

[0060] Intermediate 6 (3.5g, 11.7mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.87g, 12.8mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (80mg, 0.12mmol), potassium carbonate (3.23g, 23.4mmol) were dissolved in 60mL of dioxane and 10mL of water, purged with nitrogen gas three times, and stirred at 100°C for 10 hours. After cooling, the mixture was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 2.4g of a solid (Intermediate 7). Yield 66%.

[0061] 8. Synthesis of intermediate N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-homoserine (intermediate 8): TIFF0007591566000078.tif24124

[0062] A dichloromethane solution of tert-butyldimethylchlorosilane (22.6 g, 150 mmol) was added dropwise to a 150 mL dichloromethane solution of N-Boc homoserine (15 g, 68 mmol) and imidazole (11.6 g, 170 mmol) under ice bath, and the mixture was allowed to react overnight. The mixture was washed with water, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. 30 mL of methanol, 30 mL of tetrahydrofuran, 30 mL of water, and 15 g of potassium carbonate were added to the residue. The mixture was stirred overnight at room temperature and concentrated to remove most of the methanol and tetrahydrofuran. The pH was adjusted to 3-4, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain 22 g of product (intermediate 8), which was used directly in the next reaction.

[0063] 9. Synthesis of intermediate N-(tert-butoxycarbonyl)-O-(tert-butyldimethylsilyl)-L-homoserine methyl ester (intermediate 9): TIFF0007591566000079.tif23119

[0064] Intermediate 8 (22g, 66mmol) and potassium carbonate (26g, 188mmol) were dissolved in N,N-dimethylformamide (100mL). Iodomethane (22.4g, 158mmol) was added dropwise to the above solution at room temperature and reacted overnight. 200mL of water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 16g of product (Intermediate 9). Yield of two steps: 67.5%.

[0065] 10. Synthesis of intermediate (S)-(4-((tert-butyldimethylsilyl)oxy)-1-oxobutan-2-yl)carbamic acid tert-butyl ester (intermediate 10): TIFF0007591566000080.tif24109

[0066] Intermediate 9 (9 g, 26 mmol) was dissolved in toluene (50 mL), and DIBAL-H (31 mL, 1.5 M) was added dropwise at −78° C. under a nitrogen gas atmosphere, and the mixture was allowed to react for 1 hour. 3 mL of methanol was added dropwise to quench the reaction. After stirring for 10 minutes, the reaction solution was poured into 1N hydrochloric acid under an ice bath, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 7.2 g of product (Intermediate 10). Yield: 87.8%.

[0067] The following are specific methods for synthesizing the target compounds of the present invention.

[0068] Example 100 Synthesis of compound (1S,4S,5R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-one (compound 100): Synthesis of (1R,2S,5S)-3-tert-butyl-2-methyl-6,6-dimethyl-4-oxo-3-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (compound 100-2): TIFF0007591566000081.tif3391

[0069] Raw material 100-1 (269 mg, 1 mmol) and sodium periodate (850 mg, 4 mmol) were dissolved in 8 mL of acetonitrile and 8 mL of water. While cooling in an ice-water bath, 5 mg of ruthenium (III) chloride was added and reacted for 5 hours. The mixture was poured into water, extracted with EA, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 112 mg of product (intermediate 100-2). Yield 40%.

[0070] Ms:284(M+H + ).

[0071] Synthesis of (1R,2S,5S)-6,6-dimethyl-4-oxo-3-azabicyclo[3.1.0]hexa-2-carboxylic acid methyl ester (intermediate 100-3): TIFF0007591566000082.tif3085

[0072] Intermediate 100-2 (283 mg, 1 mmol) was dissolved in dichloromethane, and a solution of 2M HCl in isopropyl acetate was added thereto and reacted at room temperature for 1 hour. The mixture was concentrated to obtain 165 mg of the product (Intermediate 100-3). Yield: 90%. Ms: 184 (M+H + ).

[0073] Synthesis of (1R,2S,5S)-3-(3,4-difluorophenyl)-6,6-dimethyl-4-oxo-3-azabicyclo[3.1.0]hexane-2-carboxylic acid methyl ester (Intermediate 100-4): TIFF0007591566000083.tif44122

[0074] Intermediate 100-3 (183 mg, 1 mmol), 3,4-difluorophenylboronic acid (632 mg, 4 mmol), copper acetate monohydrate (300 mg, 1.5 mmol), and triethylamine (150 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 148 mg of product (Intermediate 100-4). Yield 50%. Ms: 296 (M+H + ).

[0075] Synthesis of (1S,4S,5R)-3-(3,4-difluorophenyl)-4-(hydroxymethyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-one (Intermediate 100-5): TIFF0007591566000084.tif4483

[0076] Intermediate 100-4 (295 mg, 1 mmol) was dissolved in 10 mL of methanol, and a solution of lithium borohydride in tetrahydrofuran was added dropwise and reacted at room temperature overnight. The mixture was poured into water, extracted, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated to obtain 260 mg of crude product (Intermediate 100-5). Yield 90%. Ms: 268 (M+H + ).

[0077] Synthesis of (1R,2S,5S)-3-(3,4-difluorophenyl)-6,6-dimethyl-4-oxo-3-azabicyclo[3.1.0]hexane-2-formaldehyde (Intermediate 100-6): TIFF0007591566000085.tif4490

[0078] Intermediate 100-5 (267 mg, 1 mmol) was dissolved in 10 mL of dichloromethane, Dess-Martin (2167 mg, 5 mmol) was added, and the mixture was allowed to react at room temperature overnight. After filtration, the filtrate was concentrated to give 250 mg of crude product (Intermediate 100-6). Yield 90%. Ms: 266 (M+H + ).

[0079] Synthesis of (1S,4S,5R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((1r,4S)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hex-2-one (compound 100): TIFF0007591566000086.tif53146

[0080] Intermediate 100-6 (290 mg, 1.1 mmol) was dissolved in N,N-dimethylformamide (20 mL), and intermediate 3 (315 mg, 1 mmol) and sodium pyrosulfite (360 mg, 1.9 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 80 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 392 mg of the product (compound 100). Yield: 70%. Ms: 561 (M+H + ).

[0081] 1 HNMR(400MHz,CDCl3)δ7.71(m,3H),7.28(m,1H),7.12(m,2H),5.78(s,1H),4 .60(s,1H),3.42(s,3H),3.33(s,1H),2.42-2.28(m,9H),2.09-1.00(m,13H).

[0082] Example 101 Synthesis of compound 2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (101): Synthesis of 4-(2-hydroxyethyl)-1,3,2-dioxathiolane-2,2-dioxide (Intermediate 101-1): TIFF0007591566000087.tif21130

[0083] 1,2,4-butanetriol (10.0 g, 94.2 mmol) was added to pyridine (15.2 mL) and acetonitrile (100 mL), and thionyl chloride (34.4 mL) was added dropwise at 0°C. The reaction solution was stirred at room temperature for 15 h. After the reaction was completed, ethyl acetate (20 mL) and 0.1 M hydrochloric acid solution (10 mL) were added, and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 14.5 g of an oily product was obtained.

[0084] The above 14.5 g of oily material was dissolved in acetonitrile (200 mL) and water (40 mL), and sodium periodate (19.6 g) and ruthenium chloride hydrate (172 mg) were added, and the mixture was stirred at room temperature for 15 h to react. After the reaction was completed, the acetonitrile was removed by distillation under reduced pressure, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 13.8 g of an oily material (intermediate 101-1) was obtained. Yield 78.4%.

[0085] Synthesis of 2-(2-chloroethyl)-1-((diphenylmethylene)amino)cyclopropanecarboxylic acid ethyl ester (Intermediate 101-2): TIFF0007591566000088.tif32143

[0086] Ethyl 2-((diphenylmethylene)amino)acetoacetate (10.7 g, 40 mmol) was added to tetrahydrofuran (50 mL), sodium hydride (3.2 g, 80 mmol) was added under the condition of 0° C., the reaction solution was stirred at room temperature for 1 h, and a solution of intermediate 101-1 (7.5 g, 40 mmol) in tetrahydrofuran (20 mL) was added dropwise. After the reaction solution was stirred at room temperature for 1 h, the temperature of the reaction solution was raised to 40° C., and the reaction solution was stirred and reacted for 2 h. After the reaction solution was cooled to room temperature, it was poured into water (100 mL), extracted with ethyl acetate (50 mL×2), the organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 11.6 g of an oily substance (intermediate 101-2) was obtained. Yield 81.5%.

[0087] Synthesis of 2-azabicyclo[3.1.0]n-hexane-1-carboxylic acid ethyl ester-2-carboxylic acid tert-butyl ester (Intermediate 101-3): TIFF0007591566000089.tif32101

[0088] Intermediate 101-2 (10.7 g, 30 mmol) was added to tetrahydrofuran (50 mL) and 1 M hydrochloric acid (100 mL), and the reaction solution was stirred for 3 h at 40° C. After completion of the reaction, the solvent was removed by distillation under reduced pressure to obtain an oily product.

[0089] The above oily material was dissolved in ethanol (50 mL), potassium carbonate (27.6 g, 0.2 mol) was added, and the reaction solution was stirred at room temperature for 4 h to react, after which (Boc)2O (7.8 g, 36 mmol) was added and the reaction solution was stirred for 6 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure, ethyl acetate (50 mL) and water (30 mL) were added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 6.6 g of an oily material (intermediate 101-3) was obtained by column chromatography. Yield 85.2%.

[0090] Synthesis of 3-oxo-2-azabicyclo[3.1.0]n-hexane-1-carboxylic acid ethyl ester-2-carboxylic acid tert-butyl ester (Intermediate 101-4): TIFF0007591566000090.tif3481

[0091] Intermediate 101-3 (7.7 g, 30 mmol) oil was dissolved in acetonitrile (50 mL) and water (10 mL), sodium periodate (6.6 g) and ruthenium chloride hydrate (58 mg) were added, and the mixture was stirred at room temperature for 15 h to react. After the reaction was completed, the acetonitrile was removed by distillation under reduced pressure, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 2.1 g of (Intermediate 101-4) was obtained by column chromatography. Yield 25.5%.

[0092] Synthesis of 1-(hydroxymethyl)-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 101-5): TIFF0007591566000091.tif3774

[0093] Intermediate 101-4 (1.3 g, 5 mmol) was dissolved in methanol (10 mL), lithium borohydride (219 mg, 10 mmol) was added, and the reaction solution was stirred at 40°C for 3 h to react. After the reaction was completed, ethyl acetate (30 mL) and water (10 mL) were added, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 1.02 g of (Intermediate 101-5) was obtained by column chromatography. Yield: 89.5%.

[0094] Synthesis of 1-formyl-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 101-6): TIFF0007591566000092.tif2779

[0095] Intermediate 101-5 (909 mg, 4 mmol) was dissolved in dichloromethane (10 mL), Dess-Martin reagent (2.5 g, 6 mmol) was added, and the reaction solution was stirred at room temperature for 3 h to react. After the reaction was completed, the insoluble matter was removed by filtration, the filtrate was distilled under reduced pressure to remove the solvent, and 785 mg of (Intermediate 101-6) was obtained by column chromatography. Yield 87.2%.

[0096] Synthesis of 1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 101-7): TIFF0007591566000093.tif34126

[0097] Intermediate 3 (535 mg, 1.7 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 101-6 (428 mg, 1.9 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 h. Water (40 mL) was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 604 mg of the product (intermediate 101-7). Yield: 68.2%.

[0098] Synthesis of 1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (Intermediate 101-8): TIFF0007591566000094.tif39133

[0099] Intermediate 101-7 (521 mg, 1 mmol) was dissolved in dichloromethane (4 mL), trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 3 h to react. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product, which was used in the next reaction without purification.

[0100] Synthesis of 2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (compound 101): TIFF0007591566000095.tif50134

[0101] Intermediate 101-8 (84 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 51 mg of the product (compound 101). Yield 47.7%. Ms: 533 (M+H+), 1 H NMR:(400MHz,d6-DMSO)δ7.77(d,J=8.5Hz,1H),7.68-7.56(m,2H),7.47-7.33(m,2H),7.16(d,J=7.4Hz,1H),4.25(t,J=11.8Hz,1H) ,3.29(s,3H),2.79(d,J=18.7Hz,1H),2.37(s,3H),2.29-2.12(m,8H),2.07(dd,J=13.7,7.8Hz,1H),1.88(s,1H),1.50-1.14(m,6H).

[0102] Example 102 Synthesis of compound (1S,5S)-2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (102): Synthesis of (S)-4-(2-hydroxyethyl)-1,3,2-dioxathiolane-2,2-dioxide (Intermediate 102-1) TIFF0007591566000096.tif21130

[0103] (S)-1,2,4-butanetriol (10.0 g, 94.2 mmol) was added to pyridine (15.2 mL) and acetonitrile (100 mL), and thionyl chloride (34.4 mL) was added dropwise at 0°C. The reaction solution was stirred at room temperature for 15 h. After the reaction was completed, ethyl acetate (20 mL) and 0.1 M hydrochloric acid solution (10 mL) were added, and the mixture was extracted with ethyl acetate (10 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 14.2 g of an oily product was obtained.

[0104] The above 14.2 g of oily material was dissolved in acetonitrile (200 mL) and water (40 mL), and sodium periodate (19.2 g) and ruthenium chloride hydrate (168 mg) were added and reacted at room temperature with stirring for 15 h. After the reaction was completed, the acetonitrile was removed by distillation under reduced pressure, and the mixture was extracted with ethyl acetate (100 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 13.2 g of an oily material (intermediate 102-1) was obtained. Yield 75%.

[0105] Synthesis of (1S)-2-(2-chloroethyl)-1-((diphenylmethylene)amino)cyclopropanecarboxylic acid ethyl ester (Intermediate 102-2): TIFF0007591566000097.tif22119

[0106] Ethyl 2-((diphenylmethylene)amino)acetoacetate (10.7 g, 40 mmol) was added to tetrahydrofuran (50 mL), and NaH (3.2 g, 80 mmol) was added under the condition of 0° C., and the reaction solution was stirred at room temperature for 1 h to react, and a tetrahydrofuran solution (20 mL) of intermediate 102-1 (7.5 g, 40 mmol) was added dropwise. After stirring the reaction solution at room temperature for 1 h, the temperature of the reaction solution was raised to 40° C., and the reaction solution was stirred and reacted for 2 h. After cooling the reaction solution to room temperature, it was poured into water (100 mL), extracted with ethyl acetate (50 mL×2), the organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 11.5 g of an oily substance (intermediate 102-2) was obtained. Yield 80.5%.

[0107] Synthesis of (1S,5R)-2-azabicyclo[3.1.0]n-hexane-1-carboxylic acid ethyl ester-2-carboxylic acid tert-butyl ester (Intermediate 102-3): TIFF0007591566000098.tif32103

[0108] Intermediate 102-2 (10.7 g, 30 mmol) was added to tetrahydrofuran (50 mL) and 1 M hydrochloric acid (100 mL), and the reaction solution was stirred for 3 h at 40° C. After completion of the reaction, the solvent was removed by distillation under reduced pressure to obtain an oily product.

[0109] The above oily material was dissolved in ethanol (50 mL), potassium carbonate (27.6 g, 0.2 mol) was added, and the reaction solution was stirred at room temperature for 4 h to react, after which (Boc)2O (7.8 g, 36 mmol) was added and the reaction solution was stirred for 6 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure, ethyl acetate (50 mL) and water (30 mL) were added, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 6.4 g of an oily material (intermediate 102-3) was obtained by column chromatography. Yield 82.6%.

[0110] Synthesis of (1S,5R)-3-oxo-2-azabicyclo[3.1.0]n-hexane-1-carboxylic acid ethyl ester-2-carboxylic acid tert-butyl ester (Intermediate 102-4): TIFF0007591566000099.tif36101

[0111] Intermediate 102-3 (7.7 g, 30 mmol) oil was dissolved in acetonitrile (50 mL) and water (10 mL), sodium periodate (6.6 g) and ruthenium chloride hydrate (58 mg) were added, and the mixture was stirred at room temperature for 15 h to react. After the reaction was completed, the acetonitrile was removed by distillation under reduced pressure, and the mixture was extracted with ethyl acetate (30 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 2.3 g of (Intermediate 102-4) was obtained by column chromatography. Yield 27.5%.

[0112] Synthesis of (1S,5R)-1-(hydroxymethyl)-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 102-5): TIFF0007591566000100.tif3579

[0113] Intermediate 102-4 (1.3 g, 5 mmol) was dissolved in methanol (10 mL), lithium borohydride (219 mg, 10 mmol) was added, and the reaction solution was stirred at 40°C for 3 h to react. After the reaction was completed, ethyl acetate (30 mL) and water (10 mL) were added, and the mixture was extracted with ethyl acetate (20 mL x 2). The organic phase was washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, and filtered to obtain a filtrate. The filtrate was distilled under reduced pressure to remove the solvent, and 1.04 g of (Intermediate 102-5) was obtained by column chromatography. Yield 91.5%.

[0114] Synthesis of (1S,5S)-1-formyl-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 102-6): TIFF0007591566000101.tif3096

[0115] Intermediate 102-5 (909 mg, 4 mmol) was dissolved in dichloromethane (10 mL), Dess-Martin reagent (2.5 g, 6 mmol) was added, and the reaction solution was stirred at room temperature for 3 h to react. After the reaction was completed, the insoluble matter was removed by filtration, the filtrate was distilled under reduced pressure to remove the solvent, and 761 mg of (Intermediate 102-6) was obtained by column chromatography. Yield 84.5%.

[0116] Synthesis of (1S,5S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 102-7): TIFF0007591566000102.tif43135

[0117] Intermediate 7 (541 mg, 1.7 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 102-6 (428 mg, 1.9 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 h. Water (40 mL) was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 609 mg of the product (intermediate 102-7). Yield: 68.8%.

[0118] Synthesis of (1S,5S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (Intermediate 102-8): TIFF0007591566000103.tif46118

[0119] Intermediate 102-7 (524 mg, 1 mmol) was dissolved in dichloromethane (4 mL), trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 3 h to react. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product, which was used in the next reaction without purification.

[0120] Synthesis of (1S,5S)-2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (compound 102): TIFF0007591566000104.tif47109

[0121] Intermediate 102-8 (85 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 49 mg of product (compound 102). Yield 46.2%. Ms: 536 (M+H + ), 1 H NMR:(400MHz,d6-DMSO)δ7.77(d,J=8.5Hz,1H),7.66(s,1H),7.59(d,J=10.1Hz,1H),7.51-7.30(m,2H),7.16(d,J=8.2Hz,1 H),4.25(s,1H),2.79(d,J=18.7Hz,1H),2.37(s,3H),2.30-2.09(m,8H),2.09-2.00(m,1H),1.88(s,1H),1.57-1.09(m,6H).

[0122] Example 103 Synthesis of compound (1S,5S)-2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (103): Synthesis of (1S,5S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-oxo-2-azabicyclo[3.1.0]n-hexane-2-carboxylic acid tert-butyl ester (Intermediate 103-1): TIFF0007591566000105.tif41129

[0123] Intermediate 3 (535 mg, 1.7 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 102-6 (428 mg, 1.9 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 h. Water (40 mL) was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 589 mg of the product (intermediate 103-1). Yield: 66.5%.

[0124] Synthesis of (1R,5R)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (Intermediate 103-2): TIFF0007591566000106.tif3694

[0125] Intermediate 103-1 (521 mg, 1 mmol) was dissolved in dichloromethane (4 mL), trifluoroacetic acid (2 mL) was added, and the mixture was stirred at room temperature for 3 hours to react. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product, which was used in the next reaction without purification.

[0126] Synthesis of (1S,5S)-2-(3,4-difluorophenyl)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[3.1.0]hexan-3-one (compound 103): TIFF0007591566000107.tif44104

[0127] Intermediate 103-2 (84 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 51 mg of product (compound 103). Yield 47.5%. Ms: 533 (M+H + ), 1 H NMR:(400MHz,d6-DMSO)δ7.77(d,J=8.5Hz,1H),7.66(d,J=1.3Hz,1H),7.60(ddd,J=12. 1,7.2,2.3Hz,1H),7.41(dt,J=17.5,9.0Hz,2H),7.16(dd,J=8.5,1.5Hz,1H),4.25(t,J =12.3Hz,1H),3.29(s,3H),2.79(d,J=18.7Hz,1H),2.37(s,3H),2.29-2.12(m,8H),2.0 5(dd,J=8.5,5.8Hz,1H),1.88(s,1H),1.44(dd,J=16.9,11.3Hz,2H),1.35-1.19(m,4H).

[0128] Example 104 Synthesis of compound (R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidin-2-one (104): Synthesis of (R)-tert-butyl 4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2,2-dimethyloxazolidine-3-carboxylate (104-2): TIFF0007591566000108.tif37116

[0129] Compound 104-1 (230 mg, 1 mmol), intermediate 3 (315 mg, 1 mmol), and sodium metabisulfite (380 mg, 2 mmol) were dissolved in N,N-dimethylformamide (4 mL), heated to 80°C and reacted for 3 to 4 hours. After the reaction was completed, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and then subjected to column chromatography to obtain 300 mg of (104-2). Yield: 57%.

[0130] Synthesis of (R)-2-amino-2-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)ethanol hydrochloride (104-3): TIFF0007591566000109.tif3896

[0131] Compound 104-2 (300 mg, 1 mmol) was dissolved in methanol (2 mL) and concentrated hydrochloric acid (2 mL), and reacted overnight. After the reaction was completed, the mixture was concentrated to give 230 mg of (104-3). Yield: 96%.

[0132] (R)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidine-2-thione (Intermediate 104-4) TIFF0007591566000110.tif38104

[0133] Intermediate 104-3 (130 mg, 0.34 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, and thiophosgene (20 mg, 0.17 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 85 mg of the product (Intermediate 104-4). Yield: 60%.

[0134] Synthesis of (R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidin-2-one (compound 104): TIFF0007591566000111.tif41115

[0135] Intermediate 104-4 (83 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 50 mg of the product (compound 104). Yield 48.9%. Ms: 539 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.8-7.7(m,2H),7.65-7.61(m,1H),7.55-7.48(m,2H),7 .4-7.3(m,1H),5.75-5.73(m,1H),5.47-5.45(m,1H),4.71-4.65(m,1H),4.58-4. 55(m,1H),3.25(s,3H),2.41(s,3H),2.35-2.30(m,2H),2.25(s,3H),2.15-2.1(m ,2H),2.01-1.95(m,1H),1.80-1.75(m,1H),1.55-1.5(m,1H),1.37-1.22(m,2H).

[0136] Example 105 Synthesis of compound (R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidin-2-one (105): (R)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidin-2-one (Intermediate 105-1) TIFF0007591566000112.tif42113

[0137] Intermediate 104-3 (130 mg, 0.34 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, and triphosgene (48.3 mg, 0.17 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 85 mg of product (Intermediate 105-1). Yield: 60%.

[0138] Synthesis of (R)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)oxazolidin-2-one (compound 105): TIFF0007591566000113.tif41116

[0139] Intermediate 105-1 (83 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 50 mg of the product (compound 105). Yield 48.9%. Ms: 523 (M+H+ ), 1 H NMR(400MHz,d6-DMSO)δ7.72(d,J=8.5Hz,1H),7.53-7.58(m,2H),7.36-7.16(m,1 H),7.00-7.08(m,2H),6.21(d,J=5.9Hz,1H),4.71(t,J=8.4Hz,1H),4.37(m,2H),3 .31(s,1H),3.17(s,3H),2.23(s,3H),2.15(d,J=12.3Hz,2H),2.06(s,3H),2.01(d ,J=9.3Hz,2H),1.80(d,J=13.2Hz,1H),1.55(d,J=12.3Hz,1H),1.37-1.22(m,2H).

[0140] Example 106 Synthesis of compound (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,4-oxazepan-3-one (106): Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (Intermediate 106-1): TIFF0007591566000114.tif36118

[0141] Intermediate 10 (600 mg, 1.9 mmol) was dissolved in N,N-dimethylformamide (30 mL), and intermediate 3 (535 mg, 1.7 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 720 mg of the product (intermediate 106-1). Yield: 70.6%.

[0142] Synthesis of tert-butyl (S)-3-hydroxy-1-(1-((trans)-4-methoxycyclohexyl)-5-(3-methylisoxazol-4-yl)-1H-benzo[d]imidazole-2-propylcarbamate) (Intermediate 106-2): TIFF0007591566000115.tif38120

[0143] Intermediate 106-1 (500 mg, 0.82 mmol), potassium hydrogen fluoride (320 mg, 4.1 mmol) were dissolved in methanol (20 mL) and water (4 mL) and reacted at 30° C. overnight. The mixture was concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated to obtain 356 mg of the product (Intermediate 106-2). Yield: 90%.

[0144] Synthesis of tert-butyl 2-((S)-3-(tert-butoxycarbonylamino)-3-(1-(trans)-4-methoxycyclohexyl)-5-(3-methylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)propoxy)acetate (compound 106-3): TIFF0007591566000116.tif33112

[0145] Dissolve intermediate 106-2 (300mg, 0.62mmol) in anhydrous tetrahydrofuran (5mL), add sodium hydride (62mg, 1.55mmol) in several portions under ice bath, remove ice bath after addition, react at room temperature for half an hour, add bromoacetic acid tert-butyl ester (157mg, 0.81mmol), react for about 2-3 hours, add ammonium chloride aqueous solution, extract with ethyl acetate, dry with anhydrous sodium sulfate, and obtain 105mg of product (intermediate 106-3) by concentration column chromatography. Yield: 28%.

[0146] Synthesis of 2-((S)-3-amino-3-(1-(trans)-4-methoxycyclohexyl)-5-(3-methylisoxazol-4-yl)-1H-benzo[d]imidazole-2-acyl)propoxy)acetic acid hydrochloride (compound 106-4): TIFF0007591566000117.tif36119

[0147] Concentrated hydrochloric acid (2 mL) was added to intermediate 106-3 (105 mg, 0.18 mmol), and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the solvent was removed by rotation to obtain 80 mg of the product (intermediate 106-4). Yield: 93%.

[0148] Synthesis of (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,4-oxazepan-3-one (Intermediate 106-5): TIFF0007591566000118.tif36102

[0149] Intermediate 106-4 (80 mg, 0.17 mmol) and diisopropylethylamine (71 mg, 0.55 mmol) were dissolved in N,N-dimethylformamide, and HATU (97 mg, 0.26 mmol) was added while stirring, and the mixture was reacted at room temperature overnight with stirring. After the reaction was completed, water was added, and the mixture was extracted with ethyl acetate, dried with anhydrous sodium sulfate, concentrated, and purified with a preparation plate to obtain 48 mg of the product (intermediate 106-5). Yield: 65%.

[0150] Synthesis of (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-(trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,4-oxazepan-3-one (product 106): TIFF0007591566000119.tif40120

[0151] Intermediate 106-5 (30 mg, 0.07 mmol), 3,4-difluorophenylboronic acid (44 mg, 0.28 mmol), copper acetate monohydrate (22 mg, 0.11 mmol), and triethylamine (14 mg, 0.14 mmol) were dissolved in 5 mL of acetonitrile and reacted overnight at 30°C. After filtering, concentrating, and purifying with a preparative plate, 21 mg of product (compound 106) was obtained. Yield 56%. Ms: 551 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.86(d,J=8.5Hz,1H),7.72(d,J=1.2Hz,1H),7.40(dd,J=19.6,9.1Hz,1H),7.34-7.23 (m,1H),7.23-7.11(m,1H),6.95(d,J=8.6Hz,1H),5.70(s,1H),4.83(d,J=15.1Hz,1H),4.37(d,J=15.0Hz,2H), 3.98(d,J=12.2Hz,1H),3.40(d,J=11.3Hz,2H),3.27(s,3H),2.85-2.60(m,1H),2.42(s,3H),2.37-2.20(m,6H) ,2.17-2.07(m,1H),2.03(d,J=12.2Hz,1H),1.82(d,J=11.2Hz,1H),1.50(d,J=12.5Hz,1H),1.42-1.27(m,2H).

[0152] Example 107 Synthesis of compound 4-(2-((((2S,5S)-2-(3,4-difluorophenyl)-5-methylpyrrolidin-1-yl)methyl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (107): Synthesis of 2-((2S,5S)-2-(3,4-difluorophenyl)-5-methylpyrrolidin-1-yl)acetic acid tert-butyl ester (Intermediate 107-2): TIFF0007591566000120.tif3497

[0153] Compound 107-1 (100 mg, 0.51 mmol) and bromoacetic acid tert-butyl ester (119 mg, 0.61 mmol) were dissolved in acetonitrile (3 mL), potassium carbonate (176 mg, 1.3 mmol) was added to the reaction solution, and the mixture was stirred at room temperature overnight to react. After the reaction was completed, water was added, and the mixture was extracted three times with ethyl acetate, combined, dried over anhydrous sodium sulfate, and concentrated to obtain 155 mg of crude product (107-2). Yield: 97%.

[0154] Synthesis of 2-((2S,5S)-2-(3,4-difluorophenyl)-5-methylpyrrolidin-1-yl)acetic acid (Intermediate 107-3): TIFF0007591566000121.tif35114

[0155] The crude product 107-2 (155 mg, 0.5 mmol) was added to concentrated hydrochloric acid (3 mL) and reacted with stirring overnight. After the reaction was completed, the mixture was concentrated to give the crude product 103 mg (107-3). Yield: 71%.

[0156] Synthesis of 2-((2S,5S)-2-(3,4-difluorophenyl)-5-methylpyrrolidin-1-yl)-N-(5-(3,5-dimethylisoxazol-4-yl)-2-((trans)-4-methoxycyclohexylamino)phenyl)acetamide (Intermediate 107-4): TIFF0007591566000122.tif60145

[0157] Compound 107-3 (30 mg, 0.1 mmol), intermediate 3 (36 mg, 0.11 mmol), diisopropylethylamine (52 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (2 mL), and HATU (57 mg, 0.15 mmol) was added while stirring. The mixture was stirred overnight and reacted. After the reaction was completed, water was added, and the mixture was extracted three times with ethyl acetate, combined, dried over anhydrous sodium sulfate, concentrated, and purified by preparative plate to give 21 mg of product (intermediate 107-4). Yield: 38%.

[0158] Synthesis of 4-(2-((((2S,5S)-2-(3,4-difluorophenyl)-5-methylpyrrolidin-1-yl)methyl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (107): TIFF0007591566000123.tif4187

[0159] Intermediate 107-4 (21 mg, 0.04 mmol) was dissolved in acetic acid (3 mL), heated to 60° C., and reacted overnight. After the reaction was completed, the pH was adjusted to 9-10 with aqueous potassium carbonate solution, and the mixture was extracted three times with ethyl acetate, combined, dried over anhydrous sodium sulfate, concentrated, and purified on a preparative plate to obtain 8 mg of product (107). Yield: 37%. Ms: 535 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.72(d,J=8.5Hz,1H),7.51(d,J=1.3Hz,1H),7.42-7.31(m,1H),7.3 0-7.14(m,2H),7.10(dd,J=8.5,1.5Hz,1H),4.20(t,J=12.2Hz,1H),3.82(s,2H),3.75(t,J= 7.5Hz,1H),3.43-3.30(m,4H),3.00(dd,J=12.9,6.6Hz,1H),2.39(s,3H),2.24-1.91(m,10H ),1.74-1.48(m,3H),1.38-1.28(m,1H),0.95(dd,J=23.6,9.7Hz,1H),0.82(d,J=6.0Hz,3H).

[0160] Example 108 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-methyltetrahydropyrimidin-2(1H)-one (108): Synthesis of ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)propyl)carbamic acid tert-butyl ester (108-1) TIFF0007591566000124.tif38137

[0161] Intermediate 10 (380 mg, 1.2 mmol) was dissolved in N,N-dimethylformamide (15 mL), and intermediate 7 (318 mg, 1 mmol) and sodium metabisulfite (379 mg, 2 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 25 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain intermediate 108-1 (460 mg, 0.75 mmol). Yield: 75%.

[0162] Synthesis of (S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-hydroxypropyl)carbamic acid tert-butyl ester (Intermediate 108-2): TIFF0007591566000125.tif30104

[0163] Intermediate 108-1 (460 mg, 0.75 mmol) was dissolved in methanol (4 mL) and water (1 mL), and KHF2 (117 mg, 1.5 mmol) was added and reacted at 30° C. overnight. The mixture was concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 245 mg of intermediate 108-2. Yield: 81.5%.

[0164] Synthesis of (S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-oxypropyl)carbamic acid tert-butyl ester (Intermediate 108-3): TIFF0007591566000126.tif36116

[0165] Intermediate 108-2 (502 mg, 1 mmol) was dissolved in dichloromethane (10 mL), Dess-Martin reagent (625 mg, 1.5 mmol) was added, and the reaction solution was stirred at room temperature for 3 h to react. After the reaction was completed, the insoluble matter was removed by filtration, the filtrate was distilled under reduced pressure to remove the solvent, and 475 mg of (Intermediate 108-3) was obtained by column chromatography. Yield 95.1%.

[0166] Synthesis of (S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(methylamino)propyl)carbamic acid tert-butyl ester (Intermediate 108-4): TIFF0007591566000127.tif33124

[0167] Intermediate 108-3 (400 mg, 0.8 mmol) was dissolved in methanol (5 mL), and an alcohol solution of methylamine (25 mg, 0.8 mmol) and sodium borohydride acetate (170 mg, 0.8 mmol) were added, and the reaction solution was stirred at room temperature for 5 h to react. After the reaction was completed, the mixture was concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 371 mg of (Intermediate 108-4). Yield 90.2%.

[0168] (S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-N 3 Synthesis of -methylpropane-1,3-diamine (Intermediate 108-5): TIFF0007591566000128.tif34109

[0169] Intermediate 108-4 (309 mg, 0.6 mmol) was dissolved in methanol (5 mL), 3 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30° C. overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 228 mg of product (Intermediate 108-5). Yield: 92.5%.

[0170] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-methyltetrahydropyrimidin-2(1H)-one (Intermediate 108-6): TIFF0007591566000129.tif35112

[0171] Intermediate 108-5 (137 mg, 0.33 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, and triphosgene (48.3 mg, 0.17 mmol) was added in several portions under ice bath, and the mixture was reacted for 30 min. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 86 mg of the product (intermediate 108-6). Yield: 59.5%.

[0172] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-methyltetrahydropyrimidin-2(1H)-one (compound 108): TIFF0007591566000130.tif42106

[0173] Intermediate 108-6 (88 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 45 mg of product (compound 108). Yield 40.7%. Ms: 553 (M+H + ) Example 109 Synthesis of compound (S)-3-(4-chloro-3-fluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-methyltetrahydropyrimidin-2(1H)-one (109): TIFF0007591566000131.tif39111

[0174] Intermediate 108-6 (88 mg, 0.2 mmol), 4-chloro-3-fluorophenylboronic acid (140 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 47 mg of the product (compound 109). Yield 41.5%. Ms: 569 (M+H + ) Example 110 Synthesis of compound (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-methyldihydropyrimidine-2,4(1H,3H)-dione (110): Synthesis of (S)-N-(5-(3,5-dimethylisoxazol-4-yl)-2-((((trans)-4-methoxycyclohexyl)amino)phenyl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide (Intermediate 110-1): TIFF0007591566000132.tif39112

[0175] Intermediate 3 (630 mg, 2 mmol), (S)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxylic acid (340 mg, 2 mmol), and HATU (910 mg, 2.4 mmol) were dissolved in N,N-dimethylformamide (10 mL), triethylamine (400 mg, 4 mmol) was added, and the mixture was reacted at room temperature for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 620 mg of the product (Intermediate 110-1). Yield: 66.1%.

[0176] Synthesis of (S)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-methyldihydropyrimidine-2,4(1H,3H)-dione (Intermediate 110-2): TIFF0007591566000133.tif44111

[0177] Intermediate 110-1 (620 mg, 1.3 mmol) was dissolved in acetic acid (20 mL) and reacted at 50° C. overnight. It was concentrated, water (20 ml) was added, extracted with dichloromethane, dried with anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 180 mg of product (Intermediate 110-2). Yield: 29.8%.

[0178] Synthesis of (S)-1-(3,4-difluorophenyl)-6-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-methyldihydropyrimidine-2,4(1H,3H)-dione (compound 110): TIFF0007591566000134.tif35113

[0179] Intermediate 110-2 (90 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 35 mg of the product (compound 110). Yield 31.4%. Ms: 564 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.82(d,J=8.5Hz,1H),7.64(d,J=1.5Hz,1H),7.48(ddd,J=26.0,13.5,5.8Hz,2 H),7.17(dt,J=5.7,2.8Hz,1H),7.14-7.07(m,1H),5.86(d,J=5.0Hz,1H),4.17(t,J=12.0Hz,1H),3.69 (dd,J=16.5,6.9Hz,1H),3.37(dd,J=11.4,7.3Hz,1H),3.26(s,3H),3.11(s,3H),2.89(dt,J=16.5,8.1 Hz,1H),2.39(s,3H),2.27-2.14(m,4H),2.14-1.93(m,2H),1.81(d,J=12.1Hz,1H),1.38-1.18(m,4H).

[0180] Example 111 Synthesis of compound (R)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morpholin-3-one (111): Synthesis of 2-chloro-N-((R)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)acetamide (Intermediate 111-1): TIFF0007591566000135.tif38113

[0181] Intermediate 104-3 (100 mg, 0.24 mmol) and diisopropylethylamine (93 mg, 0.72 mmol) were dissolved in dichloromethane (3 mL), and chloroacetyl chloride (30 mg, 0.26 mmol) was added dropwise under ice bath. After the addition, the ice bath was removed. After the reaction was completed, water was added, and the mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and then subjected to column chromatography to obtain 63 mg of (111-1). Yield: 57% Synthesis of (R)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morpholin-3-one (Intermediate 111-2): TIFF0007591566000136.tif41103

[0182] Intermediate 111-1 (63 mg, 0.14 mmol) was dissolved in anhydrous tetrahydrofuran (3 mL), and sodium hydride (16 mg, 0.41 mmol) was added in several portions under an ice bath. After the addition, the ice bath was removed and the reaction was allowed to proceed at room temperature. After the reaction was completed, an aqueous ammonium chloride solution was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified on a preparation plate to obtain 35 mg of (111-2). Yield: 59% Synthesis of (R)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morpholin-3-one (compound 111): TIFF0007591566000137.tif38109

[0183] Intermediate 111-2 (35 mg, 0.08 mmol), 3,4-difluorophenylboronic acid (51 mg, 0.32 mmol), copper acetate monohydrate (24 mg, 0.12 mmol), and triethylamine (20 mg) were dissolved in 4 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 21 mg of product (compound 111). Yield 48%. Ms: 537 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.81(d,J=8.5Hz,1H),7.68(d,J=1.3Hz,1H),7.52(ddd,J=11 .9,7.4,2.3Hz,1H),7.40(dd,J=19.6,9.1Hz,1H),7.15(dd,J=8.5,1.5Hz,2H),5.89( s,1H),4.52-4.28(m,4H),4.14(dd,J=12.1,3.7Hz,1H),3.46-3.39(m,1H),3.28(s,3 H),2.39(s,3H),2.32-1.99(m,7H),1.93-1.77(m,1H),1.38(dd,J=15.6,12.8Hz,3H).

[0184] Example 112 Synthesis of compound (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (112) Synthesis of ((S)-2-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)ethyl)carbamic acid tert-butyl ester (112-1) TIFF0007591566000138.tif37115

[0185] Intermediate 112 (300 mg, 1 mmol) was dissolved in N,N-dimethylformamide (15 mL), and intermediate 3 (262 mg, 0.8 mmol) and sodium metabisulfite (379 mg, 2 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 25 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 420 mg of product (intermediate 112-1). Yield: 70.2%.

[0186] Synthesis of (S)-2-amino-2-(5-(3,5-dimethylisoxazolyl-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)ethanol (112-2) TIFF0007591566000139.tif35104

[0187] Intermediate 112-1 (420 mg, 0.7 mmol) was added to methanol (4 mL), and KHF2 (109 mg, 1.4 mmol) and concentrated hydrochloric acid (1 mL) were added, and the mixture was reacted at 30° C. overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain intermediate 112-2 (230 mg, 0.59 mmol). Yield: 84.2%.

[0188] Synthesis of (S)-2-(2-chloroacetamido)-2-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-chloroacetylethyl ester (112-3) TIFF0007591566000140.tif36119

[0189] 112-2 (230 mg, 0.59 mmol) was dissolved in dichloromethane (2 mL), N,N-diisopropylethylamine (155 mg, 1.18 mmol) and chloroacetyl chloride (133 mg, 1.18 mmol) were added, and the mixture was stirred at room temperature for 4 hours. The mixture was washed with water (2 mL), dried over anhydrous sodium sulfate, and rotary evaporated to give intermediate 112-3 (300 mg, 0.56 mmol). Yield: 95%.

[0190] Synthesis of 2-chloro-N-((S)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-hydroxyethyl)acetamide (112-4) TIFF0007591566000141.tif36105

[0191] 112-3 (300 mg, 0.56 mmol) was dissolved in tetrahydrofuran (3 mL), water (0.6 mL) and lithium hydroxide monohydrate (47 mg, 1.12 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Rotary drying was performed, dichloromethane (5 mL) was added, and the mixture was washed with water (5 mL), washed with saturated saline (5 mL), and dried over anhydrous sodium sulfate. Intermediate 112-4 (230 mg, 0.5 mmol) was obtained by rotary drying. Yield: 90%.

[0192] Synthesis of (S)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (112-5) TIFF0007591566000142.tif44122

[0193] 112-4 (230 mg, 0.5 mmol) was dissolved in tetrahydrofuran (2 mL), sodium hydride (20 mg, 0.5 mmol) was added, and the mixture was stirred at room temperature overnight. Water (4 mL) was added, and the mixture was extracted with dichloromethane (4 mL x 3). The organic phases were combined, washed with saturated saline (4 mL), dried over anhydrous sodium sulfate, and rotary evaporated. Intermediate 112-5 (191 mg, 0.45 mmol) was obtained. Yield: 90%.

[0194] Synthesis of (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (112) TIFF0007591566000143.tif42146

[0195] Intermediate 112-5 (191 mg, 0.45 mmol), 3,4-difluorophenylboronic acid (284 mg, 1.8 mmol), copper acetate monohydrate (135 mg, 0.68 mmol), and triethylamine (45 mg, 0.45 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 112 (123 mg, 0.23 mmol). Yield 52%. Ms: 537 (M+H + ).

[0196] Example 113 Synthesis of compound (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (113) Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)propyl-1-ol (113-1) TIFF0007591566000144.tif36115

[0197] Intermediate 108-1 (460 mg, 0.75 mmol) was dissolved in methanol (4 mL), and KHF2 (117 mg, 1.5 mmol) and concentrated hydrochloric acid (1 mL) were added and reacted at 30°C overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain intermediate 113-1 (240 mg, 0.60 mmol). Yield: 80%.

[0198] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (113-2): TIFF0007591566000145.tif38123

[0199] Intermediate 113-1 (240 mg, 0.60 mmol) and triethylamine (91 mg, 0.9 mmol) were dissolved in tetrahydrofuran (20 mL), and triphosgene (71 mg, 0.24 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain the product intermediate 113-2 (161 mg, 0.38 mmol). Yield: 63%.

[0200] Synthesis of (S)-4-(3,4-difluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (113) TIFF0007591566000146.tif43146

[0201] Intermediate 113-2 (161 mg, 0.38 mmol), 3,4-difluorophenylboronic acid (237 mg, 1.5 mmol), copper acetate monohydrate (115 mg, 0.57 mmol), and triethylamine (38 mg, 0.38 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 113 (160 mg, 0.3 mmol). Yield 78%. Ms: 540 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.81(d,J=8.5Hz,1H),7.73(d,J=1.0Hz,1H),7.47(ddd,J=11.7,7.4,2 .3Hz,1H),7.37(dd,J=19.5,9.2Hz,1H),7.17(dd,J=8.5,1.3Hz,1H),7.11(d,J=8.9Hz,1H),5. 83(s,1H),4.58(t,J=10.3Hz,1H),4.44-4.28(m,2H),3.40(d,J=10.8Hz,1H),2.68(t,J=13.0H z,1H),2.40(s,3H),2.30-2.01(m,8H),1.85(d,J=11.3Hz,1H),1.33(dt,J=29.3,13.7Hz,3H).

[0202] Example 114 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 114): (Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-ylpropan-1-ol (Intermediate 114-1):) TIFF0007591566000147.tif37111

[0203] Intermediate 106-1 (720 mg, 1.2 mmol) and potassium hydrogen fluoride (190 mg) were dissolved in methanol (20 mL), 5 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 310 mg of product (intermediate 114-1). Yield: 73.8%.

[0204] (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (Intermediate 114-2) TIFF0007591566000148.tif36103

[0205] Intermediate 114-1 (130 mg, 0.34 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, triphosgene (48.3 mg, 0.17 mmol) was added in several portions, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 85 mg of the product (intermediate 114-2). Yield: 60%.

[0206] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 114): TIFF0007591566000149.tif36111

[0207] Intermediate 114-2 (85 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 55 mg of the product (compound 114). Yield 51.4%. Ms: 537 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.67(d,J=8.6Hz,1H),7.59(s,1H),7.37-7.17(m,2H),7.10-6.89(m,2H),5.69(s,1H),4.45(t,J=10.5Hz, 1H), 4.23(br,2H),3.23(br,1H),3.14(s,3H),2.54(br,1H),2.27(s,3H),2.15-1.79(m,6H),1.93-1.58(m,2H),1.40-1.22(m,4H).

[0208] Example 115 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(4-fluorophenyl)-1,3-oxazinean-2-one (115): TIFF0007591566000150.tif38113

[0209] Intermediate 114-2 (85 mg, 0.2 mmol), 4-fluorophenylboronic acid (112 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 45 mg of the product (compound 115). Yield 43%. Ms: 519 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.79(d,J=8.4Hz,1H),7.73(s,1H),7.30(dd,J=8.8,5 .1Hz,2H),7.14(dd,J=16.7,8.3Hz,3H),5.76(s,1H),4.65(t,J=10.0Hz,1H), 4.36(d,J=10.5Hz,2H),3.37(d,J=5.4Hz,1H),3.27(s,3H),2.67(s,1H),2.41 (s,3H),2.32-1.93(m,8H),1.84(s,1H),1.34(t,J=12.6Hz,2H),1.16(s,1H).

[0210] Example 116 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(4-chlorophenyl)-1,3-oxazinean-2-one (Compound 116): TIFF0007591566000151.tif40117

[0211] Intermediate 114-2 (85 mg, 0.2 mmol), 4-chlorophenylboronic acid (125 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 50 mg of the product (compound 116). Yield 47%. Ms: 535 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.79(dd,J=8.4,5.1Hz,1H),7.72(d,J=1.3Hz,1H),7.39-7 .25(m,4H),7.16(dd,J=8.5,1.5Hz,1H),5.81(s,1H),4.61(t,J=10.0Hz,1H),4.35( d,J=10.2Hz,2H),3.32(s,1H),3.28(s,3H),2.67(s,1H),2.41(s,3H),2.30-2.01(m ,8H),1.84(d,J=12.3Hz,1H),1.34(dd,J=17.7,12.1Hz,2H),1.17(d,J=7.1Hz,1H).

[0212] Example 117 Synthesis of compound (S)-3-(3-fluoro-4-chlorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 117): TIFF0007591566000152.tif39113

[0213] Intermediate 114-2 (85 mg, 0.2 mmol), 3-fluoro-4-chlorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 56 mg of product (compound 117). Yield 51%. Ms: 553 (M+H + ), 1 H NMR(400MHz,CDCl3)δ7.9-7.71(m,1H),7.65-7.48(m,1H),7.42-7.1(m,4H),4.8 7(s,1H),4.46-4.17(m,1H),3.41(s,3H),2.45-2.31(m,8H),1.90-1.11(m,11H).

[0214] Example 118 Synthesis of compound (S)-3-(3,4,5-trifluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 118): TIFF0007591566000153.tif42123

[0215] Intermediate 114-2 (85 mg, 0.2 mmol), 3,4,5-trifluorophenylboronic acid (132 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 58 mg of the product (compound 118). Yield 51%. Ms: 555 (M+H + ), 1 H NMR(400MHz,CDCl3)δ7.78-7.71(m,1H),7.6-7.5(m,1H),7.45-7.35(m,1H),7.2-6.96(m, 2H), 4.87(s, 1H), 4.46-4.17(m, 1H), 3.41(s, 3H), 2.45-2.31(m, 8H), 1.90-1.11(m, 11H).

[0216] Example 119 Synthesis of compound (S)-4-(4-fluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (119) TIFF0007591566000154.tif34116

[0217] Intermediate 113-2 (161 mg, 0.38 mmol), 4-fluorophenylboronic acid (210 mg, 1.5 mmol), copper acetate monohydrate (115 mg, 0.57 mmol), and triethylamine (38 mg, 0.38 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 119 (149 mg, 0.29 mmol). Yield 75%. Ms: 522 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.79(d,J=8.6Hz,1H),7.73(s,1H),7.29(s,2H),7.14(d,J=7.3Hz,3H),5.77(s,1H),4.63(d,J= 9.0Hz,1H),4.34(s,2H),2.67(s,1H),2.41(s,3H),2.26-1.96(m,8H),1.84(s,1H),1.31(d,J=14.5Hz,3H),1.13(s,1H).

[0218] Example 120 Synthesis of compound (S)-4-(3,4,5-trifluorophenyl)-5-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)morphine-3-one (120) TIFF0007591566000155.tif43146

[0219] Intermediate 113-3 (161 mg, 0.38 mmol), 3,4,5-trifluorophenylboronic acid (264 mg, 1.5 mmol), copper acetate monohydrate (115 mg, 0.57 mmol), and triethylamine (38 mg, 0.38 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 120 (162 mg, 0.29 mmol). Yield 75%. Ms: 558 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.82(d,J=8.5Hz,1H),7.73(d,J=1.3Hz,1H),7.35(dd,J=9.2,6.5 Hz,2H),7.17(dd,J=8.5,1.5Hz,1H),5.88(d,J=2.3Hz,1H),4.51(t,J=10.3Hz,1H),4.42-4 .30(m,2H),3.41(dd,J=12.7,8.8Hz,1H),2.68(dd,J=17.5,8.6Hz,1H),2.40(s,3H),2.29 -2.04(m,7H),1.88(d,J=11.8Hz,1H),1.37(dd,J=23.7,9.3Hz,3H),1.24(d,J=6.2Hz,1H).

[0220] Example 121 Synthesis of compound tert-butyl 4-((S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate (121): TIFF0007591566000156.tif41114

[0221] Intermediate 114-2 (85 mg, 0.2 mmol), (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid (132 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 60 mg of the product (compound 121). Yield 51%. Ms: 606 (M+H + ).

[0222] Example 122 Synthesis of compound (S)-3-(3-fluoro-4-chlorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (122): TIFF0007591566000157.tif41124

[0223] Intermediate 113-3 (42 mg, 0.1 mmol), 3-fluoro-4-chlorophenylboronic acid (63 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 35 mg of the product (compound 122). Yield 66.1%. Ms: 556 (M+H + ),1H NMR(400MHz,d6-DMSO)δ7.82(d,J=8.3Hz,1H),7.72(s,1H),7.53(t,J=8.6Hz,1H),7.47(d,J=10.7Hz,1H),7.16(t,J=9.9Hz,2H),5.89(s,1H), 4.56(t,J=10.7Hz,1H),4.35(d,J=11.1Hz,2H),3.39(br,1H),2.68(br,1H),2.40(s,3H),2.30-2.00(m,7H),1.88(br,1H),1.37-1.13(m,4H).

[0224] Example 123 Synthesis of compound (S)-3-(4-chlorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 123): TIFF0007591566000158.tif49145

[0225] Intermediate 113-3 (85 mg, 0.2 mmol), 4-chlorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 56 mg of the product (compound 123). Yield 51%. Ms: 538 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.79(dd,J=8.4,5.1Hz,1H),7.72(d,J=1.3Hz,1H),7.35(dt,J=26.3,8.6Hz,4H),7.16(dd,J=8.5,1.5Hz,1H), 5.88(d, J =2.3Hz,1H),4.51(t, J =10.3Hz,1H),4.42-4.27(m,2H),3.41(dd, J =12.7,8.8Hz,1H),2.68(dd, J =17.5,8.6Hz,1H),2.40(s,3H),2.34-2.02(m,7H),1.88(d, J =11.8Hz,1H),1.45-1.31(m,3H),1.26-1.21(m,1H).

[0226] Example 124 Synthesis of compound (S)-3-(6-chloropyridin-3-yl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 124): TIFF0007591566000159.tif42119

[0227] Intermediate 113-3 (85 mg, 0.2 mmol), 6-chloro-3-boronic acid pyridine (125 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 60 mg of the product (compound 124). Yield 55.7%. Ms: 539 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ8.4(s,1H),7.78-7.75(m,1H),7.75(s,1H),7.51-7.49(m,1H),7.3-7.25(m,1H),7.2-7.15(m,1H), 5.88(m, 1H),4.51-4.5(m,1H),4.42-4.27(m,2H),,2.75-2.7(m,1H),2.40(s,3H),2.34-2.02(m,8H),1.88-1.8(m, 1H), 1.45-1.31(m, 3H), 1.26-1.21(m, 1H).

[0228] Example 125 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-oxadion-2-one (125): Synthesis of tert-butyl 4-((S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one-3-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Intermediate 125-1): TIFF0007591566000160.tif40119

[0229] Intermediate 113-3 (85 mg, 0.2 mmol), (1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-yl)boronic acid (132 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 60 mg of the product (compound 125-1). Yield 51%. Ms: 609 (M+H + ).

[0230] Synthesis of 4-((S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one-3-yl)-5,6-dihydropyridine-1(2H) (Intermediate 125-2): TIFF0007591566000161.tif4388

[0231] Intermediate 125-1 (61 mg, 0.1 mmol) was dissolved in a solution of hydrogen chloride in isopropyl acetate, reacted overnight, and concentrated to dryness to obtain 55 mg of product (Intermediate 125-2). Yield 93%. Ms: 509 (M+H + ).

[0232] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1,3-oxadion-2-one (compound 125): TIFF0007591566000162.tif49109

[0233] The hydrochloride of intermediate 125-2 (508 mg, 1 mmol) was dissolved in methanol and neutralized with triethylamine until neutral, then acetic acid (60 mg, 1 mmol), paraformaldehyde (150 mg, 5 mmol) were added, and sodium triacetoxyborohydride (850 mg, 4 mmol) was added in several portions, and the mixture was allowed to react overnight. The mixture was poured into water, extracted, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 260 mg of the product (compound 125). Yield 50%. Ms: 523 (M+H + ), 1 H NMR(400MHz,CDCl3)δ7.68(d,J=1.1Hz,1H),7.57(d,J=8.4Hz,1H),7.13(dd,J= 8.4,1.5Hz,1H),5.62(s,1H),5.26(s,1H),4.74(t,J=10.6Hz,1H),4.34-4.15( m,2H),3.36(t,J=11.0Hz,1H),3.14(s,2H),2.91-2.62(m,3H),2.59-2.51(m,2 H),2.48-2.39(m,6H),2.35-2.22(m,6H),2.05-1.85(m,3H),1.64-1.40(m,3H).

[0234] Example 126 Synthesis of compound ((S)-3-(4-chloro-3-methoxyphenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (126): TIFF0007591566000163.tif37104

[0235] Intermediate 113-3 (85 mg, 0.2 mmol), 3-methoxy-4-chlorophenylboronic acid (149 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 65 mg of the product (compound 126). Yield 57.2%. Ms: 568 (M+H + ).

[0236] Example 127 Synthesis of compound 2-chloro-5-((S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-2-yl)-2-oxo-1,3-oxazinean-3-yl)benzonitrile (127): TIFF0007591566000164.tif42115

[0237] Intermediate 113-3 (85 mg, 0.2 mmol), 3-cyano-4-chlorophenylboronic acid (145 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 64 mg of the product (compound 127). Yield 56.9%. Ms: 563 (M+H + ).

[0238] Example 128 Synthesis of compound (S)-3-(3,4-dichlorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (128): TIFF0007591566000165.tif41124

[0239] Intermediate 113-3 (85 mg, 0.2 mmol), 3,4-dichlorophenylboronic acid (135 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 57 mg of the product (compound 128). Yield 51%. Ms: 572 (M+H + ), 1 H NMR(400MHz,CDCl3)δ7.79-7.4(m,3H),7.35-7.05(m,3H),5.88(d, J =2.3Hz,1H),4.51(t, J =10.3Hz,1H),4.42-4.27(m,2H),3.41(dd, J =12.7,8.8Hz,1H),2.68(dd, J =17.5,8.6Hz,1H),2.40(s,3H),2.34-2.02(m,7H),1.88(d, J =11.8Hz,1H),1.45-1.31(m,3H),1.26-1.21(m,1H).

[0240] Example 129 Synthesis of compound (S)-3-(3-chloro-4-fluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (129): TIFF0007591566000166.tif49145

[0241] Intermediate 113-3 (85 mg, 0.2 mmol), 3-chloro-4-fluorophenylboronic acid (135 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 56 mg of the product (compound 129). Yield 51%. Ms: 556 (M+H + ),1 H NMR(400MHz,d6-DMSO)δ7.95-7.32(m,3H),7.25-6.65(m,3H),5.88(d, J =2.3Hz,1H),4.51(t, J =10.3Hz,1H),4.42-4.27(m,2H),3.41(dd, J =12.7,8.8Hz,1H),2.68(dd, J =17.5,8.6Hz,1H),2.40(s,3H),2.34-2.02(m,7H),1.88(d, J =11.8Hz,1H),1.45-1.31(m,3H),1.26-1.21(m,1H).

[0242] Example 130 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(3-chlorophenyl)-1,3-oxazinean-2-one (130): TIFF0007591566000167.tif29104

[0243] Intermediate 113-3 (85 mg, 0.2 mmol), 3-chlorophenylboronic acid (125 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 55 mg of the product (compound 130). Yield 51%. Ms: 538 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.80(d,J=8.5Hz,1H),7.73(d,J=1.3Hz,1H),7.48(d,J=1. 9Hz,1H),7.27(dt,J=8.5,4.9Hz,2H),7.22-7.10(m,2H),5.89(s,1H),4.63(t,J=10 .0Hz,1H),4.37(d,J=10.5Hz,2H),3.38(s,1H),2.67(t,J=12.6Hz,1H),2.40(s,3H) ),2.30-2.01(m,8H),1.84(d,J=12.9Hz,1H),1.45-1.30(m,2H),1.20-1.15(m,1H).

[0244] Example 131 Synthesis of compound (S)-3-(1-methylpyrazol-4-yl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-deuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (131): TIFF0007591566000168.tif35104

[0245] Intermediate 113-3 (85 mg, 0.2 mmol), 1-methylpyrazole-4-phenylboronic acid (105 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 51 mg of the product (compound 131). Yield 51%. Ms: 508 (M+H + ), 1H NMR(400MHz,d6-DMSO)7.68(d,J=1.1Hz,1H),7.57(d,J=8.4Hz,1H),7.45(s,1H),7.35(s,1H),7.13(dd,J=8.4,1.5Hz,1H),5.88(d, J =2.3Hz,1H),4.51(t, J =10.3Hz,1H),4.42-4.27(m,2H),3.85(s,3H),3.41(dd, J =12.7,8.8Hz,1H),2.68(dd, J =17.5,8.6Hz,1H),2.40(s,3H),2.34-2.02(m,7H),1.88(d, J =11.8Hz,1H),1.45-1.31(m,3H),1.26-1.21(m,1H).

[0246] Example 132 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(4-methoxyphenyl)-1,3-oxazinean-2-one (Compound 132): TIFF0007591566000169.tif37104

[0247] Intermediate 113-3 (40 mg, 0.1 mmol), 4-methoxyphenylboronic acid (60 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 45 mg of the product (compound 132). Yield 90.3%. Ms: 534 (M+H +),1H NMR(400MHz,d6-DMSO)δ7.77(d,J=8.5Hz,1H),7.73(s,1H),7.15(d,J=8.8Hz,3H),6.82(d,J=8.9Hz,2H),5.71(s,1H),4.69(t,J=9.9Hz, 1H),4.41-4.21(m,2H),3.67(s,3H),3.35(br,1H),2.71-2.55(m,1H),2.41(s,3H),2.29-1.94(m,7H),1.82(br,1H),1.40-1.22(m,4H).

[0248] Example 133 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((1 trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(3-fluoro-4-methoxyphenyl)-1,3-oxazinean-2-one (133): TIFF0007591566000170.tif39121

[0249] Intermediate 113-3 (40 mg, 0.1 mmol), 3-fluoro-4-methoxyphenylboronic acid (65 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 35 mg of the product (compound 133). Yield 63.7%. Ms: 552 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.79(d,J=8.5Hz,1H),7.73(s,1H),7.25-7.12(m,2H),7.11-6.96(m,2H).5.71(s,1H),4.69(t,J=9.9Hz,1H) ,4.41-4.21(m,2H),3.67(s,3H),3.35(br,1H),2.71-2.55(m,1H),2.41(s,3H),2.29-1.94(m,7H),1.82(br,1H),1.40-1.22(m,4H).

[0250] Example 134 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(3,5-difluorophenyl)-1,3-oxazinean-2-one (Compound 134): TIFF0007591566000171.tif34109

[0251] Intermediate 113-3 (40 mg, 0.1 mmol), 3,5-difluorophenylboronic acid (65 mg, 0.8 mmol), copper acetate monohydrate (30 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 33 mg of the product (compound 134). Yield 61.4%. Ms: 540 (M+H + ),1H NMR(400MHz,d6-DMSO)δ7.83(d,J=8.0Hz,1H),7.73(s,1H),7.14(dd,J=31.5,8.0Hz,4H).5.91(s,1H),4.59(t,J=9.9Hz,1 H),4.41-4.21(m,2H),3.35(br,1H),2.71-2.55(m,1H),2.41(s,3H),2.29-1.94(m,7H),1.82(br,1H),1.40-1.22(m,4H).

[0252] Example 135 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(3-chloro-5-fluorophenyl)-1,3-oxazinean-2-one (135): TIFF0007591566000172.tif37113

[0253] Intermediate 113-3 (40 mg, 0.1 mmol), 3-chloro-5-fluorophenylboronic acid (68 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 25 mg of the product (compound 135). Yield 45.4%. Ms: 556 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.82(d,J=8.9Hz,1H),7.73(s,1H),7.34(s,1H),7.30(d,J=8.8Hz,1H),7.18(t,J=9.0Hz,2H).5.91(s,1H),4.59 (t,J=9.9Hz,1H),4.41-4.21(m,2H),3.35(br,1H),2.71-2.55(m,1H),2.41(s,3H),2.29-1.94(m,7H),1.82(br,1H),1.40-1.22(m,4H).

[0254] Example 136 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(4-bromophenyl)-1,3-oxazinean-2-one (136): TIFF0007591566000173.tif36118

[0255] Intermediate 113-3 (40 mg, 0.1 mmol), 4-bromophenylboronic acid (65 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 40 mg of the product (compound 136). Yield 69.3%. Ms: 582,584 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.80(d,J=8.5Hz,1H),7.72(s,1H),7.50(d,J=8.7Hz,2H),7.24(d,J=8.7Hz,2H),7.16(d,J=8.4Hz,1H),5.82(s,1H), 4.61(t,J=10.1Hz,1H),4.35(d,J=10.8Hz,2H),3.36(br,1H),2.65(br,1H),2.41(s,3H),2.28-1.98(m,7H),1.86(br,1H),1.42-1.12(m,4H).

[0256] Example 137 Synthesis of compound (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-trideuteromethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-3-(3-methyl-4-fluorophenyl)-1,3-oxazinean-2-one (137): TIFF0007591566000174.tif41111

[0257] Intermediate 113-3 (40 mg, 0.1 mmol), 3-methyl-4-fluorophenylboronic acid (61 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 38 mg of the product (compound 137). Yield 71.4%. Ms: 536 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.78(d,J=8.5Hz,1H),7.73(s,1H),7.29(d,J=7.1Hz, 1H),7.16(d,J=8.4Hz,1H),7.02(d,J=7.8Hz,2H),5.77(s,1H),4.66(t,J=9.8H z,1H),4.35(d,J=11.1Hz,2H),3.41-3.34(m,1),2.71-2.57(m,1H),2.41(s,3 H),2.24(s,3H),2.21-1.91(m,7H),1.82(d,J=10.5Hz,1H),1.46-1.01(m,4H).

[0258] Example 138 Synthesis of compound 4-(2-(3',4'-difluoro-6-methoxy-[1,1'-biphenyl]-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (138): Synthesis of 3',4'-difluoro-6-methoxy-[1,1'-biphenyl]-2-formaldehyde (Intermediate 138-1): TIFF0007591566000175.tif26129

[0259] 2-Bromo-3-methoxybenzaldehyde (100mg, 0.47mmol), 3,4-difluorophenylboronic acid (96mg, 0.61mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (17mg, 0.023mmol), potassium carbonate (129mg, 0.94mmol) were dissolved in 15mL of dioxane and 3mL of water, purged with nitrogen gas three times, and stirred at 100°C for 6 hours. Cooled, extracted with ethyl acetate (30mL x 3), combined with ethyl acetate, washed with saturated saline (20mL), dried the organic layer over anhydrous sodium sulfate, concentrated, and obtained 83mg of oil (intermediate 138-1) by column chromatography. Yield 71.6%.

[0260] Synthesis of 4-(2-(3',4'-difluoro-6-methoxy-[1,1'-biphenyl]-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (compound 138): TIFF0007591566000176.tif36110

[0261] Intermediate 138-1 (33 mg, 0.13 mmol) and intermediate 3 (35 mg, 0.11 mmol) were dissolved in 5 mL of glacial acetic acid, heated to 50° C. and stirred for 3 hours. The mixture was cooled, the pH was adjusted to 8-9 with saturated potassium carbonate solution, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed once with saturated saline (15 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 36 mg of a white solid (compound 138). Yield 59.7%. Ms: 554 (M+H + ), 1 HMNR: 1 H NMR(400MHz,d6-DMSO)δ7.74(d,J=8.5Hz,1H),7.64(s,1H),7.55(t,J=8.0Hz,1H),7. 39(t,J=13.3Hz,2H),7.27(dd,J=19.0,8.7Hz,1H),7.12(dd,J=13.8,8.0Hz,2H),6.97 (s,1H),3.82(s,3H),3.73(t,J=12.3Hz,1H),3.22(s,3H),2.41(s,3H),2.24(s,3H),2 .15-2.04(m,2H),1.96(s,2H),1.64(s,1H),1.24(d,J=9.8Hz,2H),1.18-0.98(m,2H).

[0262] Example 139 Synthesis of compound 4-(2-(3-(3,4-difluorophenyl)-2-methoxypyridin-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (139): Synthesis of 3-(3,4-difluorophenyl)-2-methoxyisonicotinic acid (139-1). TIFF0007591566000177.tif23109

[0263] 3-Bromo-2-methoxyisonicotinic acid (350 mg, 1.52 mmol), 3,4-difluorophenylboronic acid (360 mg, 2.28 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (30 mg, 0.041 mmol), potassium carbonate (627 mg, 4.55 mmol) were dissolved in 60 mL of dioxane and 20 mL of water, purged with nitrogen gas three times, stirred at 100 ° C for 6 hours, cooled, filtered under reduced pressure, adjusted to PH 2-3 with dilute hydrochloric acid, extracted with ethyl acetate (50 mL × 3), combined organic phase, washed once with saturated saline (20 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 280 mg of solid (intermediate 139-1).

[0264] Synthesis of (3-(3,4-difluorophenyl)-2-methoxypyridin-4-yl)methanol (139-2): TIFF0007591566000178.tif28103

[0265] LAH (80 mg, 2.11 mmol) was dissolved in 20 mL of tetrahydrofuran and stirred at room temperature for 30 minutes. Intermediate 139-1 (280 mg, 1.06 mmol) was added in several portions under ice bath and reacted at room temperature for 2 hours. The reaction was quenched with 2 mL of acetone, and 2 mL of 15% sodium hydroxide solution, 3 mL of water, and 20 g of magnesium sulfate were added. The mixture was stirred at room temperature for 1 hour and filtered under reduced pressure. The mixture was concentrated and subjected to column chromatography to obtain 185 mg of oil (Intermediate 139-2). Yield 69.8%.

[0266] Synthesis of 3-(3,4-difluorophenyl)-2-methoxyisonicotinaldehyde (139-3): TIFF0007591566000179.tif31100

[0267] Intermediate 139-2 (185 mg, 0.74 mmol) was dissolved in 30 mL of dichloromethane, and PCC (557 mg, 2.21 mmol) was added in several portions. The mixture was stirred at room temperature for 1 hour. The mixture was filtered under reduced pressure, and the filtrate was concentrated and subjected to column chromatography to obtain 130 mg of an oil (139-3). Yield: 70.8%.

[0268] Synthesis of 4-(2-(3-(3,4-difluorophenyl)-2-methoxypyridin-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (compound 139): TIFF0007591566000180.tif40105

[0269] Intermediate 139-3 (40 mg, 0.16 mmol) and intermediate 3 (45.6 mg, 0.15 mmol) were dissolved in 5 mL of glacial acetic acid and reacted at 50°C for 3 hours. The mixture was cooled, the pH was adjusted to 8-9 with saturated potassium carbonate solution, extracted with ethyl acetate (30 mL x 3), the organic phases were combined, washed once with saturated saline (20 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 45 mg of solid (139). Yield 57%. Ms: 545 (M+H + ), 1 H NMR(400MHz,CDCl3)δ8.35(s,1H),7.72(s,1H),7.49(t,J=11.7Hz,1H),7.13(d,J=8.2Hz,2H),7.02(d,J=3.8Hz,2H),4.03(s,3H), 3.72(s,1H),3.35(s,3H),3.17(d,J=10.9Hz,1H),2.45(s,3H),2.32(s,3H),2.10(dd,J=42.9,23.2Hz,4H),1.27(d,J=12.5Hz,5H).

[0270] Example 140 Synthesis of compound 6-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-4'-fluorobiphenyl-2-carbonitrile (140): Synthesis of 2-bromo-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)benzonitrile (Intermediate 140-1): TIFF0007591566000181.tif33107

[0271] Compound 3 (315 mg, 1 mmol) and 2-bromo-3-cyanobenzaldehyde (210 mg, 1 mmol) were dissolved in acetic acid (5 mL), and the reaction solution was heated to 60°C to react. After the reaction was completed, the pH was adjusted to 9-10 with an aqueous potassium carbonate solution, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and then subjected to column chromatography to obtain 285 mg of (140-1). Yield: 57%.

[0272] Synthesis of 6-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-4'-fluorobiphenyl-2-carbonitrile (compound 140): TIFF0007591566000182.tif3298

[0273] Intermediate 140-1 (285 mg, 0.57 mmol), p-fluorophenylboronic acid (95 mg, 0.68 mmol), potassium carbonate, bis(diphenylphosphino)ferrocene]dichloropalladium (44 mg, 0.06 mmol) were dissolved in dioxane (5 mL) and water (1 mL). The reaction solution was replaced with nitrogen gas, heated to 80°C and maintained at 80°C overnight. After the reaction was completed, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and then subjected to column chromatography to obtain 187 mg of (compound 140). Yield: 63%. Ms: 521 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ8.22(dd,J=7.8,1.2Hz,1H),7.89(dd,J=7.7,1.2Hz,1H),7.85-7.57(m,4H),7.44-6.89(m,4H),3.65(d,J=12.4 Hz,1H),3.28(d,J=11.0Hz,1H),3.21(s,3H),2.42(s,3H),2.24(s,3H),2.11-2.00(m,2H),1.91(s,2H),1.62(s,1H),1.19-1.02(m,3H).

[0274] Example 141 Synthesis of compound 4-(2-(3',4'-difluoro-6-methoxy-[1,1'-biphenyl]-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (Compound 141): Synthesis of 4'-fluoro-6-methoxy-[1,1'-biphenyl]-2-formaldehyde (Intermediate 141-1): TIFF0007591566000183.tif27133

[0275] 2-Bromo-3-methoxybenzaldehyde (100mg, 0.47mmol), 4-fluorophenylboronic acid (85mg, 0.61mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (17mg, 0.023mmol), potassium carbonate (129mg, 0.93mmol) were dissolved in 15mL of dioxane and 3mL of water, purged with nitrogen gas three times, and stirred at 100°C for 6 hours. Cooled, extracted with ethyl acetate (30mL x 3), combined with ethyl acetate, washed with saturated saline (20mL x 2), dried the organic layer over anhydrous sodium sulfate, concentrated, and obtained 80mg of oil (intermediate 141-1) by column chromatography. Yield 74.4%.

[0276] Synthesis of 4-(2-(3',4'-difluoro-6-methoxy-[1,1'-biphenyl]-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole (compound 141): TIFF0007591566000184.tif41106

[0277] Intermediate 141-1 (30 mg, 0.13 mmol) and intermediate 3 (34 mg, 0.11 mmol) were dissolved in 5 mL of glacial acetic acid, heated to 50° C. and stirred for 3 hours. The mixture was cooled, the pH was adjusted to 8-9 with saturated potassium carbonate solution, extracted with ethyl acetate (20 mL×2), the organic phases were combined, washed once with saturated saline (15 mL), the organic phase was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 35 mg of a white solid (compound 141). Yield 61.7%. Ms: 526 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.71(d,J=8.5Hz,1H),7.63(d,J=1.2Hz,1H),7.52(t,J=8 .0Hz,1H),7.36(d,J=8.1Hz,1H),7.26(s,2H),7.10(ddd,J=25.8,13.2,4.9Hz,4H) ,3.82(d,J=14.8Hz,3H),3.67(t,J=12.0Hz,1H),3.26(s,1H),3.21(s,3H),2.41( s, 3H), 2.24 (s, 3H), 2.13-1.87 (m, 5H), 1.57 (d, J=12.7Hz, 1H), 1.08-0.94 (m, 2H).

[0278] Example 142 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (142): Synthesis of (R)-N-(4-bromo-2-nitrophenyl)tetrahydrofuran-3-amine (Intermediate 142-1): TIFF0007591566000185.tif30126

[0279] 4-Bromo-1-fluoro-2-nitrobenzene (1.1 g, 5 mmol), (R)-tetrahydrofuran-3-amine (0.43 g, 5 mmol) and potassium carbonate (1.4 g, 10 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, 200 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 1.2 g of a solid (Intermediate 142-1). Yield 83.9%. Ms: 287 (M+H + ).

[0280] Synthesis of (R)-4-bromo-N1-(tetrahydrofuran-3-yl)benzene-1,2-diamine (Intermediate 142-2): TIFF0007591566000186.tif3393

[0281] Intermediate 142-1 (1.2 g, 4.2 mmol) and aqueous ammonia (10 mL) were dissolved in 50 mL of tetrahydrofuran and 50 mL of water, and sodium dithionite (10.9 g, 63 mmol) was added and stirred at room temperature overnight. The organic layer was separated by standing, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 0.8 g of a solid (intermediate 142-2). Yield 74.4%. Ms: 257 (M+H + ).

[0282] Synthesis of (R)-4-(3,5-dimethylisoxazol-4-yl)-N1-(tetrahydrofuran-3-yl)benzene-1,2-diamine (Intermediate 142-3): TIFF0007591566000187.tif26109

[0283] Intermediate 142-2 (0.8 g, 3 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (0.74 g, 3.3 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (20 mg, 0.03 mmol), potassium carbonate (0.8 g, 6 mmol) were dissolved in 20 mL of dioxane and 4 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C. for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 0.65 g of a solid (intermediate 142-3). Yield 79%. Ms: 274 (M + H + ).

[0284] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (Intermediate 142-4): TIFF0007591566000188.tif31127

[0285] Intermediate 10 (600 mg, 1.9 mmol) was dissolved in N,N-dimethylformamide (30 mL), and intermediate 142-3 (491 mg, 1.8 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 564 mg of the product (intermediate 142-4). Yield: 55%.

[0286] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl-propan-1-ol (Intermediate 142-5): TIFF0007591566000189.tif30115

[0287] Intermediate 142-4 (684 mg, 1.2 mmol) and potassium hydrogen fluoride (190 mg) were dissolved in methanol (20 mL), and 5 mL of concentrated hydrochloric acid was added and reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 300 mg of product (intermediate 142-5). Yield: 70%. Ms: 357 (M+H + ).

[0288] (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (Intermediate 142-6) TIFF0007591566000190.tif37141

[0289] Intermediate 142-5 (117 mg, 0.33 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, and triphosgene (48.3 mg, 0.17 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 80 mg of the product (intermediate 142-6). Yield: 63.4%. Ms: 383 (M+H + ).

[0290] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 142): TIFF0007591566000191.tif33118

[0291] Intermediate 142-6 (46 mg, 0.12 mmol), 3,4-difluorophenylboronic acid (77 mg, 0.5 mmol), copper acetate monohydrate (30 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 27 mg of the product (compound 142). Yield 45%. Ms: 495 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.73(dd,J=19.0,10.5Hz,2H),7.54-7.30(m,2H),7.25(d,J=8. 4Hz,1H),7.12(d,J=8.7Hz,1H),5.80(s,1H),5.32(s,1H),4.48(t,J=10.2Hz,1H),4.41 -4.16(m,2H),3.91(d,J=10.5Hz,1H),3.68(dt,J=27.2,8.4Hz,2H),2.83-2.61(m,1H), 2.50-2.44(m,1H),2.41(s,3H),2.26(d,J=11.9Hz,4H),2.03(dd,J=18.8,10.6Hz,1H).

[0292] Example 143 Synthesis of compound ((S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((cis)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (143): Synthesis of 4-bromo-N-(((cis)-3-methoxycyclobutyl)-2-nitroaniline (Intermediate 143-1): TIFF0007591566000192.tif31113

[0293] 4-Bromo-1-fluoro-2-nitrobenzene (1.1 g, 5 mmol), (cis)-3-methoxycyclobutyl-1-amine (0.55 g, 5.5 mmol) and potassium carbonate (2.1 g, 15 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, 200 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 1.2 g of a solid (Intermediate 143-1). Yield 79.7%.

[0294] Synthesis of 4-bromo-N1-((cis)-3-methoxycyclobutyl)benzene-1,2-diamine (Intermediate 143-2): TIFF0007591566000193.tif39100

[0295] Intermediate 143-1 (1.2 g, 4 mmol) and aqueous ammonia (5 mL) were dissolved in 30 mL of tetrahydrofuran and 30 mL of water, sodium dithionite (8.2 g, 40 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 0.9 g of a solid (intermediate 143-2). Yield 83%.

[0296] Synthesis of 4-(3,5-dimethylisoxazol-4-yl)-N1-(((cis)-3-methoxycyclobutyl)benzene-1,2-diamine (Intermediate 143-3): TIFF0007591566000194.tif37126

[0297] Intermediate 143-2 (0.9 g, 3.3 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (0.81 g, 3.6 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (80 mg, 0.12 mmol), potassium carbonate (0.91 g, 6.6 mmol) were dissolved in 30 mL of dioxane and 3 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C. for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 530 mg of a solid (intermediate 143-3). Yield 55%.

[0298] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((cis)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (intermediate 143-4): TIFF0007591566000195.tif31115

[0299] Intermediate 10 (600 mg, 1.9 mmol) was dissolved in N,N-dimethylformamide (30 mL), and intermediate 143-3 (530 mg, 1.8 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 620 mg of the product (intermediate 143-4). Yield: 57%.

[0300] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((cis)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-ylpropan-1-ol (Intermediate 143-5): TIFF0007591566000196.tif3295

[0301] Intermediate 143-4 (620 mg, 1.06 mmol) and potassium hydrogen fluoride (190 mg) were dissolved in methanol (20 mL), and 5 mL of concentrated hydrochloric acid was added and reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 230 mg of product (intermediate 143-5). Yield: 58.9%.

[0302] (S)-4-(1-(((cis)-3-methoxycyclobutyl)-5-(3-methylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Intermediate 143-6) TIFF0007591566000197.tif2891

[0303] Intermediate 143-5 (230 mg, 0.60 mmol) and triethylamine (190 mg, 1.86 mmol) were dissolved in 20 mL of tetrahydrofuran, triphosgene (48.3 mg, 0.17 mmol) was added in several portions, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 150 mg of the product (intermediate 143-6). Yield: 61%.

[0304] Synthesis of ((S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((cis)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 143): TIFF0007591566000198.tif2899

[0305] Intermediate 143-6 (50 mg, 0.12 mmol), 3,4-difluorophenylboronic acid (77 mg, 0.5 mmol), copper acetate monohydrate (30 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 25 mg of the product (compound 143). Yield 43.4%. Ms: 509 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.67(d,J=8.6Hz,1H),7.59(s,1H),7.37-7.17(m,2H), 7.10-6.89(m,2H),5.69(s,1H),4.93-4.75(m,1H),4.38-4.27(m,1H),4.27-4. 15(m,1H),3.84(p,J=6.9Hz,1H),3.28(s,3H),3.02-2.85(m,2H),2.85-2.65(m ,2H),2.41(s,3H),2.35-2.27(m,1H),2.24(s,3H),2.05(dd,J=9.6,4.3Hz,1H).

[0306] Example 114 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (144): Synthesis of (trans)-3-((4-bromo-2-nitrophenyl)amino)cyclobutanol (Intermediate 144-1): TIFF0007591566000199.tif37112

[0307] 4-Bromo-1-fluoro-2-nitrobenzene (2.53 g, 11.5 mmol), (trans)-3-aminocyclobutanol (1.0 g, 11.5 mmol) and potassium carbonate (3.97 g, 28.8 mmol) were dissolved in acetonitrile (30 mL), heated to 80° C. and stirred for 5 hours. After cooling, 50 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 2.8 g of a solid (Intermediate 144-1). Yield 85.2%.

[0308] Synthesis of 4-bromo-N-((trans)-3-methoxycyclobutyl)-2-nitroaniline (Intermediate 144-2): TIFF0007591566000200.tif4086

[0309] Intermediate 144-1 (2.58 g, 9 mmol) and sodium hydride (0.72 g, 18 mmol) were dissolved in 20 mL of tetrahydrofuran, and iodomethane (1.92 g, 13.5 mmol) was added dropwise under ice bath, and the mixture was reacted overnight. The mixture was poured into ice water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 1.86 g of product (intermediate 144-2). Yield 68.5%.

[0310] 4-Bromo-N 1 Synthesis of -((trans)-3-methoxycyclobutyl)benzene-1,2-diamine (Intermediate 144-3): TIFF0007591566000201.tif4086

[0311] Intermediate 144-2 (1.8 g, 6 mmol) and aqueous ammonia (5 mL) were dissolved in 75 mL of tetrahydrofuran and 75 mL of water, sodium dithionite (16.6 g, 81 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 1.4 g of a solid (intermediate 144-3). Yield 85.5%.

[0312] 4-(3,5-Dimethylisoxazol-4-yl)-N 1 Synthesis of -((trans)-3-methoxycyclobutyl)benzene-1,2-diamine (Intermediate 144-4): TIFF0007591566000202.tif4092

[0313] Intermediate 144-3 (1.6 g, 6 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (1.48 g, 6.6 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (40 mg, 0.06 mmol), potassium carbonate (1.66 g, 12 mmol) were dissolved in 30 mL of dioxane and 5 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C for 10 h. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 1.2 g of a solid (intermediate 144-4). Yield 68.5%.

[0314] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)propyl)carbamic acid tert-butyl ester (intermediate 144-5): TIFF0007591566000203.tif41146

[0315] Intermediate 10 (600 mg, 1.9 mmol) was dissolved in N,N-dimethylformamide (30 mL), and intermediate 144-4 (461 mg, 1.7 mmol) and sodium pyrosulfite (720 mg, 3.8 mmol) were added, and the mixture was reacted at 80° C. for 5 h. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 732 mg of the product (intermediate 114-5). Yield: 73.6%.

[0316] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutane)-1H-benzo[d]imidazol-2-yl)propan-1-ol (Intermediate 144-6): TIFF0007591566000204.tif43138

[0317] Intermediate 144-5 (702 mg, 1.2 mmol) and potassium hydrogen fluoride (190 mg) were dissolved in methanol (20 mL), 5 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30° C. overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 285 mg of product (intermediate 144-6). Yield: 64.2%.

[0318] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazin-2-one (Intermediate 144-7): TIFF0007591566000205.tif43134

[0319] Intermediate 144-6 (122 mg, 0.33 mmol) and triethylamine (49 mg, 0.48 mmol) were dissolved in 20 mL of tetrahydrofuran, and triphosgene (48.3 mg, 0.17 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 min. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 82 mg of the product (intermediate 144-7). Yield: 62.4%.

[0320] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 144): TIFF0007591566000206.tif43145

[0321] Intermediate 144-7 (79 mg, 0.2 mmol), 3,4-difluorophenylboronic acid (127 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30 °C overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 43 mg of product (compound 144). Yield 42.5%. Ms: 509 (M+H + ), 1 HNMR:(400MHz,d6-DMSO)δ7.87-7.74(m,2H),7.55-7.43(m,1H),7.37(dd,J=19.4,9. 2Hz,1H),7.22(d,J=7.5Hz,1H),7.16(s,1H),5.76(s,1H),5.23-5.10(m,1H),4.43(t ,J=10.0Hz,1H),4.32(d,J=10.6Hz,1H),4.21(s,1H),3.23(s,3H),2.99-2.77(m,2H) ,2.66(d,J=11.9Hz,1H),2.54(d,J=6.9Hz,1H),2.44-2.27(m,4H),2.27-2.10(m,4H).

[0322] Example 145 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (145) Synthesis of intermediate N-(4-bromo-2-nitrobenzene)tetrahydro-2H-pyran-4-amine (145-1) TIFF0007591566000207.tif3493

[0323] 4-Bromo-1-fluoro-2-nitrobenzene (3.38 g, 15.4 mmol), 4-aminotetrahydropyran (1.56 g, 15.4 mmol) and potassium carbonate (5.34 g, 38.6 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 h. Cooled, water (200 mL) was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain solid compound 145-1 (3.9 g, 13.1 mmol). Yield 85%.

[0324] 4-Bromo-N 1 Synthesis of -(tetrahydro-2H-pyran-4-yl)benzene-1,2-diamine (145-2): TIFF0007591566000208.tif35101

[0325] Intermediate 145-1 (3.9 g, 13.1 mmol) and aqueous ammonia (10 mL) were dissolved in tetrahydrofuran (150 mL) and water (150 mL), sodium dithionite (9.2 g, 52.4 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 145-2 (2.14 g, 7.9 mmol). Yield 60%.

[0326] 4-(3,5-Dimethylisoxazol-4-yl)-N 1 Synthesis of -(tetrahydro-2H-pyran-4-yl)benzene-1,2-diamine (145-3). TIFF0007591566000209.tif41142

[0327] 145-2 (2.14 g, 7.9 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.11 g, 9.48 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (58 mg, 0.08 mmol), potassium carbonate (2.18 g, 15.8 mmol) were dissolved in dioxane (60 mL) and water (10 mL), purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 145-3 (1.54 g, 5.37 mmol). Yield 68%.

[0328] Synthesis of (S)-(3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)propyl)carbamic acid tert-butyl ester (145-4) TIFF0007591566000210.tif37146

[0329] Intermediate 10 (380 mg, 1.2 mmol) was dissolved in N,N-dimethylformamide (15 mL), and intermediate 7 (287 mg, 1 mmol) and sodium metabisulfite (379 mg, 2 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 25 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain intermediate 145-4 (420 mg, 0.72 mmol). Yield: 72%.

[0330] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)propyl-1-ol (145-5) TIFF0007591566000211.tif38118

[0331] 145-4 (420 mg, 0.72 mmol) was dissolved in methanol (4 mL), and KHF2 (109 mg, 1.4 mmol) and concentrated hydrochloric acid (1 mL) were added and reacted at 30°C overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain intermediate 145-5 (213 mg, 0.58 mmol). Yield: 80%.

[0332] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (145-6). TIFF0007591566000212.tif38126

[0333] Intermediate 145-5 (213 mg, 0.58 mmol) and triethylamine (87 mg, 0.87 mmol) were dissolved in tetrahydrofuran (20 mL), and triphosgene (68 mg, 0.23 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain the product intermediate 145-6 (149 mg, 0.37 mmol). Yield: 65%.

[0334] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (145) TIFF0007591566000213.tif38145

[0335] Intermediate 145-6 (149 mg, 0.37 mmol), 3,4-difluorophenylboronic acid (230 mg, 1.48 mmol), copper acetate monohydrate (110 mg, 0.55 mmol), and triethylamine (37 mg, 0.37 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 145 (141 mg, 0.27 mmol). Yield 75%. Ms: 509 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.76(d,J=1.1Hz,1H),7.74(d,J=8.5Hz,1H),7.46(ddd,J=11.9,7.4,2.5Hz,1H),7. 37(dd,J=19.6,9.1Hz,1H),7.21(dd,J=8.5,1.6Hz,1H),7.16-7.09(m,1H),5.85(s,1H),4.69-4.52(m,2H), 4.36(d,J=10.6Hz,1H),4.06-3.91(m,2H),3.51(dd,J=22.0,11.0Hz,2H),2.81-2.65(m,1H),2.41(s,3H),2 .33(ddd,J=20.5,12.5,4.4Hz,2H),2.24(s,3H),1.92(s,1H),1.82(d,J=12.2Hz,1H),1.29(d,J=9.9Hz,1H).

[0336] Example 146 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (146): Synthesis of (S)-N-(4-bromo-2-nitrophenyl)tetrahydrofuran-3-amine (146-1): TIFF0007591566000214.tif30127

[0337] 4-Bromo-1-fluoro-2-nitrobenzene (3.38 g, 15.4 mmol), (S)-tetrahydrofuran-3-amine hydrochloride (1.9 g, 15.4 mmol) and potassium carbonate (5.34 g, 38.6 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, 200 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 4 g of a solid (Intermediate 146-1). Yield 91%.

[0338] Synthesis of (S)-4-bromo-N1-(tetrahydrofuran-3-yl)benzene-1,2-diamine (146-2): TIFF0007591566000215.tif3393

[0339] Intermediate 146-1 (4 g, 14 mmol) and aqueous ammonia (10 mL) were dissolved in 50 mL of tetrahydrofuran and 50 mL of water, sodium dithionite (9.8 g, 56 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 2.5 g of a solid (intermediate 146-2). Yield 70%.

[0340] Synthesis of (S)-4-(3,5-dimethylisoxazol-4-yl)-N1-(tetrahydrofuran-3-yl)benzene-1,2-diamine (146-3): TIFF0007591566000216.tif29119

[0341] Intermediate 146-2 (2.5 g, 10 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.7 g, 12 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (770 mg, 1 mmol), potassium carbonate (3.3 g, 24 mmol) were dissolved in 60 mL of dioxane and 10 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 1.3 g of a solid (intermediate 146-3). Yield 48%.

[0342] Synthesis of tert-butyl (S)-3-(tert-butyldimethylsilaneoxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (146-4): TIFF0007591566000217.tif31127

[0343] Intermediate 146-3 (273 mg, 1 mmol) was dissolved in N,N-dimethylformamide (3 mL), and intermediate 3 (380 mg, 1.2 mmol) and sodium metabisulfite (380 mg, 2 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 260 mg of the product (intermediate 146-4). Yield: 46%.

[0344] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-ylpropan-1-ol (Intermediate 146-5): TIFF0007591566000218.tif31115

[0345] Intermediate 146-4 (260 mg, 0.46 mmol) and potassium hydrogen fluoride (144 mg, 1.84 mmol) were dissolved in methanol (5 mL), and 5 mL of concentrated hydrochloric acid was added and reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 145 mg of product (intermediate 146-5). Yield: 88%.

[0346] Synthesis of (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (146-6) TIFF0007591566000219.tif37141

[0347] Intermediate 146-5 (145 mg, 0.41 mmol) and triethylamine (166 mg, 1.64 mmol) were dissolved in 20 mL of tetrahydrofuran, and triphosgene (38 mg, 0.13 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 88 mg of the product (intermediate 146-6). Yield: 56%.

[0348] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-tetrahydrofuran-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 146): TIFF0007591566000220.tif40143

[0349] Intermediate 146-6 (88 mg, 0.23 mmol), 3,4-difluorophenylboronic acid (144 mg, 0.9 mmol), copper acetate monohydrate (69 mg, 0.35 mmol), and triethylamine (47 mg, 0.46 mmol) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 58 mg of the product (compound 146). Yield 51%. Ms: 595 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.73(dd,J=19.0,10.5Hz,2H),7.54-7.30(m,2H),7.25(d,J=8. 4Hz,1H),7.12(d,J=8.7Hz,1H),5.80(s,1H),5.32(s,1H),4.48(t,J=10.2Hz,1H),4.41 -4.16(m,2H),3.91(d,J=10.5Hz,1H),3.68(dt,J=27.2,8.4Hz,2H),2.83-2.61(m,1H), 2.50-2.44(m,1H),2.41(s,3H),2.26(d,J=11.9Hz,4H),2.03(dd,J=18.8,10.6Hz,1H).

[0350] Example 147 Synthesis of compound (S)-4-(1-(1-acetylpiperidin-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-3-(3,4-difluorophenyl)-1,3-oxadiazin-2-one (147) Synthesis of 4-((4-bromo-2-nitrobenzene)amino)piperidine-1-formic acid tert-butyl ester (147-1): TIFF0007591566000221.tif4192

[0351] 4-Bromo-1-fluoro-2-nitrobenzene (3.38 g, 15.4 mmol), 4-amino-1-formic acid tert-butyl ester (3.08 g, 15.4 mmol) and potassium carbonate (5.34 g, 38.6 mmol) were dissolved in acetonitrile (50 mL), heated to 80° C. and stirred for 5 hours. After cooling, water (200 mL) was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain solid compound 147-1 (5.5 g, 13.9 mmol). Yield 90%.

[0352] Synthesis of N-(4-bromo-2-nitrobenzene)piperidine-4-amino (147-2). TIFF0007591566000222.tif4090

[0353] 147-1 (5.5 g, 13.9 mmol) was dissolved in methanol (50 mL), concentrated hydrochloric acid (10 mL) was added, and the mixture was stirred at room temperature overnight. The pH was adjusted to 8 with saturated aqueous sodium bicarbonate, extracted with dichloromethane, dried over anhydrous sodium sulfate, and rotary evaporated to give solid 147-2 (3.96 g, 13.2 mmol). 95%.

[0354] Synthesis of 1-(4-((4-bromo-2-nitrobenzene)amine)piperidin-1-yl)ethanone (147-3) TIFF0007591566000223.tif4495

[0355] 147-2 (3.96 g, 13.2 mmol) was dissolved in DCM (40 mL), and acetyl chloride (1.1 g, 14.5 mmol) was added dropwise while stirring at room temperature. After the addition was completed, stirring was continued at room temperature. After the reaction was completed, water (10 mL) was added to wash the reaction mixture, and then saturated saline (10 mL) was added, and the mixture was dried over anhydrous sodium sulfate and rotary dried to obtain 147-3 (4.06 g, 11.9 mmol). Yield 90%.

[0356] Synthesis of 1-(4-((2-amino-4-bromophenyl)amino)piperidin-1-yl)ethanone (147-4) TIFF0007591566000224.tif3698

[0357] 147-3 (4.06 g, 11.9 mmol) and aqueous ammonia (10 mL) were dissolved in tetrahydrofuran (150 mL) and water (150 mL), sodium dithionite (8.3 g, 47.6 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 147-4 (2.41 g, 7.7 mmol). Yield 65%.

[0358] Synthesis of 1-(4-((2-amino-4-(3,5-dimethylisoxazol-4-yl)phenyl)amino)piperidin-1-yl)ethanone (147-5) TIFF0007591566000225.tif38109

[0359] 147-4 (2.41 g, 7.7 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.06 g, 9.24 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (58 mg, 0.08 mmol), potassium carbonate (2.18 g, 15.8 mmol) were dissolved in dioxane (60 mL) and water (10 mL), purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 147-5 (1.77 g, 5.39 mmol). Yield 70%.

[0360] Synthesis of (S)-tert-butyl(1-(1-(1-acetylpiperidin-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-3-((tert-butyldimethylsilyl)oxy)propyl)carbamic acid tert-butyl ester (147-6): TIFF0007591566000226.tif34121

[0361] Intermediate 10 (380 mg, 1.2 mmol) was dissolved in N,N-dimethylformamide (15 mL), and intermediate 147-5 (328 mg, 1 mmol) and sodium metabisulfite (379 mg, 2 mmol) were added and reacted at 80° C. for 5 hours. 25 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain intermediate 147-6 (450 mg, 0.72 mmol). Yield: 72%.

[0362] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-benzo[d]imidazol-2-yl)propyl-1-ol (147-7) TIFF0007591566000227.tif3798

[0363] 147-6 (450 mg, 0.72 mmol) was dissolved in methanol (4 mL), and KHF2 (109 mg, 1.4 mmol) and concentrated hydrochloric acid (1 mL) were added and reacted at 30°C overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain intermediate 147-7 (237 mg, 0.58 mmol). Yield: 80%.

[0364] Synthesis of (S)-4-(1-(1-acetylpiperidin-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (147-8) TIFF0007591566000228.tif47128

[0365] Intermediate 147-7 (237 mg, 0.58 mmol) and triethylamine (87 mg, 0.87 mmol) were dissolved in tetrahydrofuran (20 mL), and triphosgene (68 mg, 0.23 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain the product intermediate 147-8 (161 mg, 0.37 mmol). Yield: 65%.

[0366] Synthesis of (S)-4-(1-(1-acetylpiperidin-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-3-(3,4-difluorophenyl)-1,3-oxadiazin-2-one (147) TIFF0007591566000229.tif34107

[0367] Intermediate 147-8 (161 mg, 0.37 mmol), 3,4-difluorophenylboronic acid (230 mg, 1.48 mmol), copper acetate monohydrate (110 mg, 0.55 mmol), and triethylamine (37 mg, 0.37 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain compound 147 (148 mg, 0.27 mmol). Yield 75%. Ms: 550 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.75(d,J=1.4Hz,1H),7.72(d,J=8.2Hz,1H),7.51-7.43(m,1H),7.38(dd,J=19. 0,9.6Hz,1H),7.18(d,J=8.5Hz,1H),7.12(d,J=7.6Hz,1H),5.84(s,1H),4.57(dd,J=23.4,11.8Hz,3H),4 .35(d,J=10.8Hz,1H),4.05-3.88(m,1H),3.19(dd,J=24.5,12.3Hz,1H),2.67(dt,J=24.7,12.5Hz,2H), 2.40(s,3H),2.31(d,J=12.7Hz,1H),2.22(d,J=8.0Hz,4H),2.15-1.99(m,4H),1.89(s,1H),1.31(s,1H).

[0368] Example 148 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (148) Synthesis of N-(4-bromo-2-nitrophenyl)-1-methylpiperidin-4-amine (148-1) TIFF0007591566000230.tif3876

[0369] 147-2 (3.96g, 13.2mmol) was dissolved in THF (40mL), sodium hydride (60% dispersion in mineral oil, 0.79g, 19.8mmol) was added, and the mixture was stirred at room temperature for 15 minutes. Iodomethane (3.7g, 26.4mmol) was added, and after the dropwise addition, stirring was continued at room temperature. After the reaction was completed, water (40mL) was added to wash the mixture, and the mixture was extracted with dichloromethane (20mL x 3), washed with saturated saline (40mL), dried over anhydrous sodium sulfate, and dried by rotary evaporation to obtain 148-1 (3.74g, 11.9mmol). Yield 90%.

[0370] 4-Bromo-N 1Synthesis of -(1-methylpiperidin-4-yl)benzene-1,2-diamine (148-2) TIFF0007591566000231.tif39101

[0371] 148-1 (3.74 g, 11.9 mmol) and aqueous ammonia (10 mL) were dissolved in tetrahydrofuran (150 mL) and water (150 mL), sodium dithionite (8.3 g, 47.6 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 148-2 (2.19 g, 7.7 mmol). Yield 65%.

[0372] 4-(3,5-Dimethylisoxazol-4-yl)-N 1 Synthesis of -(1-methylpiperidin-4-yl)benzene-1,2-diamine (148-3). TIFF0007591566000232.tif43122

[0373] 148-2 (2.19 g, 7.7 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (2.06 g, 9.24 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (58 mg, 0.08 mmol), potassium carbonate (2.18 g, 15.8 mmol) were dissolved in dioxane (60 mL) and water (10 mL), purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain solid 148-3 (1.62 g, 5.39 mmol). Yield 70%.

[0374] Synthesis of (S)-(3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)propyl)carbamic acid tert-butyl ester (148-4) TIFF0007591566000233.tif33127

[0375] Intermediate 10 (380 mg, 1.2 mmol) was dissolved in N,N-dimethylformamide (15 mL), and intermediate 148-3 (300 mg, 1 mmol) and sodium metabisulfite (379 mg, 2 mmol) were added and reacted at 80° C. for 5 hours. 25 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain intermediate 148-4 (430 mg, 0.72 mmol). Yield: 72%.

[0376] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)propyl-1-ol (148-5). TIFF0007591566000234.tif38113

[0377] 148-4 (430 mg, 0.72 mmol) was dissolved in methanol (4 mL), and KHF2 (109 mg, 1.4 mmol) and concentrated hydrochloric acid (1 mL) were added and reacted at 30°C overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain intermediate 148-5 (222 mg, 0.58 mmol). Yield: 80%.

[0378] Synthesis of (S)-4-(1-(1-methylpiperidin-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (148-6) TIFF0007591566000235.tif38114

[0379] Intermediate 148-5 (222 mg, 0.58 mmol) and triethylamine (87 mg, 0.87 mmol) were dissolved in tetrahydrofuran (20 mL), and triphosgene (68 mg, 0.23 mmol) was added in several portions under ice bath, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain the product intermediate 148-6 (151 mg, 0.37 mmol). Yield: 65%.

[0380] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (148) TIFF0007591566000236.tif31110

[0381] Intermediate 148-6 (151 mg, 0.37 mmol), 3,4-difluorophenylboronic acid (230 mg, 1.48 mmol), copper acetate monohydrate (110 mg, 0.55 mmol), and triethylamine (37 mg, 0.37 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to give compound 148 (140 mg, 0.27 mmol). Yield 75%. Ms: 522 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.75(s,1H),7.69(d,J=8.4Hz,1H),7.54-7.43(m,1H) ,7.36(dd,J=19.2,9.5Hz,1H),7.19(d,J=8.4Hz,1H),7.12(s,1H),5.82(s,1H) ,4.58(t,J=10.2Hz,1H),4.43-4.24(m,2H),2.88(dd,J=24.3,9.5Hz,2H),2.6 9(s,1H),2.40(s,3H),2.32-2.17(m,8H),2.08(s,4H),1.79(d,J=11.2Hz,1H).

[0382] Example 149 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 149): Synthesis of 3-((4-bromo-2-nitrophenyl)amino)pyrrolidine-1-carboxylic acid (R)-tert-butyl ester (intermediate 149-1): TIFF0007591566000237.tif30115

[0383] 4-Bromo-1-fluoro-2-nitrobenzene (1.1 g, 5 mmol), (R) 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (1.1 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) were dissolved in acetonitrile (20 mL), heated to 80° C. and stirred for 5 hours. Cooled, 100 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 1.4 g of a solid (Intermediate 149-1). Yield 69%.

[0384] Synthesis of (R)-N-(4-bromo-2-nitrophenyl)pyrrolidin-3-amine (Intermediate 149-2): TIFF0007591566000238.tif39106

[0385] 149-1 (1.3 g, 3.3 mmol) was dissolved in methanol (50 mL), 2 ml of concentrated hydrochloric acid was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated to remove methanol, and the pH was adjusted to 9-10 with sodium carbonate. The mixture was extracted five times with dichloromethane, and the organic phases were combined and concentrated to obtain 0.7 g of a solid (intermediate 149-2). Yield 64%.

[0386] Synthesis of (R)-N-(4-bromo-2-nitrophenyl)-1-methylpyrrolidin-3-amine (Intermediate 149-3): TIFF0007591566000239.tif37106

[0387] 149-2 (0.6g, 2.1mmol) was dissolved in 1,2-dichloroethane (20mL), 5ml of aqueous formaldehyde solution was added, sodium triacetoxyborohydride (2.1g, 10mmol) was further added, and the mixture was heated to 40℃ and stirred for 10 hours. After cooling, 50mL of water was added, the organic phase was separated, the aqueous phase was extracted twice with dichloromethane, the organic phases were combined, concentrated, and 420mg of a solid (intermediate 149-3) was obtained by column chromatography. Yield 68%.

[0388] Synthesis of (R)-4-bromo-N1-(1-methylpyrrolidin-3-yl)benzene-1,2-diamine (Intermediate 149-4): TIFF0007591566000240.tif3896

[0389] Intermediate 149-3 (430 mg, 1.4 mmol) and aqueous ammonia (5 mL) were dissolved in 20 mL of tetrahydrofuran and 20 mL of water, and sodium dithionite (3.2 g, 14 mmol) was added and stirred at room temperature overnight. The organic layer was separated by standing, and the aqueous layer was extracted with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 340 mg of a solid (intermediate 149-4). Yield 88%.

[0390] Synthesis of (R)-4-(3,5-dimethylisoxazol-4-yl)-N1-(1-methylpyrrolidin-3-yl)benzene-1,2-diamine (Intermediate 149-5): TIFF0007591566000241.tif32111

[0391] Intermediate 149-4 (340 mg, 1.2 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (300 mg, 1.3 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (80 mg, 0.12 mmol), potassium carbonate (330 mg, 2.4 mmol) were dissolved in 10 mL of dioxane and 1 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 240 mg of a solid (intermediate 149-5). Yield 67%.

[0392] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (Intermediate 149-6): TIFF0007591566000242.tif33123

[0393] Intermediate 10 (310 mg, 1 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 150-5 (240 mg, 0.84 mmol) and sodium pyrosulfite (570 mg, 3 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 120 mg of the product (intermediate 149-6). Yield: 19%.

[0394] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)propan-1-ol (Intermediate 149-7): TIFF0007591566000243.tif31105

[0395] Intermediate 149-6 (120 mg, 0.2 mmol) and potassium hydrogen fluoride (100 mg) were dissolved in methanol (10 mL), 2 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 60 mg of the product (intermediate 149-7). Yield: 79%.

[0396] (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadion-2-one (Intermediate 149-8) TIFF0007591566000244.tif30102

[0397] Intermediate 149-7 (60 mg, 0.16 mmol) and triethylamine (32 mg, 0.32 mmol) were dissolved in 20 mL of tetrahydrofuran, triphosgene (12 mg, 0.04 mmol) was added in several portions, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 45 mg of the product (intermediate 149-8). Yield: 71%.

[0398] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((R)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 149): TIFF0007591566000245.tif39142

[0399] Intermediate 149-8 (45 mg, 0.11 mmol), 3,4-difluorophenylboronic acid (60 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 25 mg of the product (compound 149). Yield 54.3%. Ms: 508 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ8.07(t,J=8.5Hz,1H),7.74(s,1H),7.51-7.29(m,2H),7.23(d ,J=9.1Hz,1H),7.10(d,J=8.6Hz,1H),5.88(br,1H),5.19(br,1H),4.60-4.45(m,1H), 4.35(d,J=10.8Hz,1H),3.10(br,1H),2.93-2.85(m,1H),2.70-2.67(m,1H),2.41(s,3 H),2.33(s,3H),2.38-2.12(m,2H),2.24(s,3H),2.12-1.80(m,2H),1.60-1.44(m,1H).

[0400] Example 150 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (150): Synthesis of 3-((4-bromo-2-nitrophenyl)amino)pyrrolidine-1-carboxylic acid (S)-tert-butyl ester (Intermediate 150-1): TIFF0007591566000246.tif28106

[0401] 4-Bromo-1-fluoro-2-nitrobenzene (1.1 g, 5 mmol), (S) 3-aminopyrrolidine-1-carboxylic acid tert-butyl ester (1.1 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) were dissolved in acetonitrile (20 mL), heated to 80° C. and stirred for 5 hours. Cooled, 100 mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 1.3 g of a solid (Intermediate 150-1). Yield 67.5%.

[0402] Synthesis of (S)-N-(4-bromo-2-nitrophenyl)pyrrolidin-3-amine (Intermediate 150-2): TIFF0007591566000247.tif3697

[0403] 150-1 (1.3 g, 3.3 mmol) was dissolved in methanol (50 mL), 2 ml of concentrated hydrochloric acid was added, and the mixture was stirred at room temperature for 5 hours. The mixture was concentrated to remove methanol, and the pH was adjusted to 9-10 with sodium carbonate. The mixture was extracted five times with dichloromethane, and the organic phases were combined and concentrated to obtain 0.6 g of a solid (intermediate 150-2). Yield: 62.3%.

[0404] Synthesis of (S)-N-(4-bromo-2-nitrophenyl)-1-methylpyrrolidin-3-amine (Intermediate 150-3): TIFF0007591566000248.tif37106

[0405] 150-2 (0.6g, 2.1mmol) was dissolved in 1,2-dichloroethane (20mL), 5ml of aqueous formaldehyde solution was added, sodium triacetoxyborohydride (2.1g, 10mmol) was further added, and the mixture was heated to 40℃ and stirred for 10 hours. After cooling, 50mL of water was added, the organic phase was separated, the aqueous phase was extracted twice with dichloromethane, the organic phases were combined, concentrated, and 430mg of a solid (intermediate 150-3) was obtained by column chromatography. Yield 69.8%.

[0406] Synthesis of (S)-4-bromo-N1-(1-methylpyrrolidin-3-yl)benzene-1,2-diamine (Intermediate 150-4): TIFF0007591566000249.tif3896

[0407] Intermediate 150-3 (430 mg, 1.4 mmol) and aqueous ammonia (5 mL) were dissolved in 20 mL of tetrahydrofuran and 20 mL of water, sodium dithionite (3.2 g, 14 mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, the aqueous layer was extracted with ethyl acetate, the organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 340 mg of a solid (intermediate 150-4). Yield 88%.

[0408] Synthesis of (S)-4-(3,5-dimethylisoxazol-4-yl)-N1-(1-methylpyrrolidin-3-yl)benzene-1,2-diamine (Intermediate 150-5): TIFF0007591566000250.tif29102

[0409] Intermediate 150-4 (340 mg, 1.2 mmol), 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (300 mg, 1.3 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (80 mg, 0.12 mmol), potassium carbonate (330 mg, 2.4 mmol) were dissolved in 10 mL of dioxane and 1 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C. for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 240 mg of a solid (intermediate 150-5). Yield 67%.

[0410] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (Intermediate 105-6): TIFF0007591566000251.tif31118

[0411] Intermediate 10 (310 mg, 1 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 150-5 (240 mg, 0.84 mmol) and sodium pyrosulfite (570 mg, 3 mmol) were added, and the mixture was reacted at 80° C. for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 120 mg of the product (intermediate 150-6). Yield: 19%.

[0412] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)propan-1-ol (Intermediate 150-7): TIFF0007591566000252.tif32109

[0413] Intermediate 150-6 (120 mg, 0.2 mmol) and potassium hydrogen fluoride (100 mg) were dissolved in methanol (10 mL), 2 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 60 mg of the product (intermediate 150-7). Yield: 79%.

[0414] (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadion-2-one (Intermediate 150-8) TIFF0007591566000253.tif34117

[0415] Intermediate 150-7 (60 mg, 0.16 mmol) and triethylamine (32 mg, 0.32 mmol) were dissolved in 20 mL of tetrahydrofuran, triphosgene (12 mg, 0.04 mmol) was added in several portions, and the mixture was allowed to react for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 45 mg of the product (intermediate 150-8). Yield: 71%.

[0416] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((S)-1-methylpyrrolidin-3-yl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 150): TIFF0007591566000254.tif30116

[0417] Intermediate 150-8 (45 mg, 0.11 mmol), 3,4-difluorophenylboronic acid (60 mg, 0.4 mmol), copper acetate monohydrate (30 mg, 0.15 mmol), and triethylamine (30 mg) were dissolved in 5 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 25 mg of the product (compound 150). Yield 54.3%. Ms: 508 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ8.07(t,J=8.5Hz,1H),7.74(s,1H),7.51-7.29(m,2H),7.23(d ,J=9.1Hz,1H),7.10(d,J=8.6Hz,1H),5.88(br,1H),5.19(br,1H),4.60-4.45(m,1H), 4.35(d,J=10.8Hz,1H),3.10(br,1H),2.93-2.85(m,1H),2.70-2.67(m,1H),2.41(s,3 H),2.33(s,3H),2.38-2.12(m,2H),2.24(s,3H),2.12-1.80(m,2H),1.60-1.44(m,1H).

[0418] Example 151 Synthesis of compound (S)-3-(4-chloro-3-fluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-3-methoxycyclobutyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 151): TIFF0007591566000255.tif37110

[0419] Intermediate 144-6 (79 mg, 0.2 mmol), 4-chloro-3-fluorophenylboronic acid (140 mg, 0.8 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 46 mg of product (compound 151). Yield 43.4%. Ms: 525 (M+H + ), 1HNMR:(400MHz,d6-DMSO)δ7.82(d,J=8.5Hz,1H),7.75(s,1H),7.59-7.40(m,2H), 7.26-7.15(m,2H),5.81(s,1H),5.21(p,J=8.7Hz,1H),4.47-4.36(m,1H),4.33(d ,J=10.8Hz,1H),4.22(t,J=6.5Hz,1H),3.22(d,J=12.5Hz,3H),3.00-2.82(m,2H) ,2.68(t,J=12.8Hz,1H),2.55(s,1H),2.38(d,J=20.6Hz,4H),2.27-2.12(m,4H).

[0420] Example 152 Synthesis of compound (S)-6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one (152) (S)-N-(5-bromo-2-(((trans)-4-methoxycyclohexyl)amine)phenyl)-6-oxopiperidine-2-formamide (152-1) TIFF0007591566000256.tif47120

[0421] Intermediate 2 (2.98 g, 10 mmol) was dissolved in dichloromethane (30 mL), and (S)-2-piperidone-6-carboxylic acid (1.43 g, 10 mmol), propylphosphonic anhydride (50% in EA, 6.36 g, 10 mmol) and DIEA (1.54 g, 12 mmol) were added. After the addition was completed, the mixture was stirred at room temperature overnight, rotovapped and subjected to column chromatography to obtain 152-1 (3.4 g, 8 mmol). Yield 80%.

[0422] Synthesis of (S)-6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (Intermediate 152-2) TIFF0007591566000257.tif43105

[0423] 152-1 (3.4 g, 8 mmol) was added to acetic acid (30 mL), stirred at 50° C. for 3 days, rotary evaporated, dissolved in dichloromethane, washed with saturated sodium bicarbonate solution, and dried over anhydrous sodium sulfate. Rotary evaporated and purified by column chromatography to give 152-2 (1.95 g, 4.8 mmol). Yield 60%.

[0424] Synthesis of (S)-6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one (152) TIFF0007591566000258.tif40120

[0425] 152-2 (1.95 g, 4.8 mmol), 3,4-difluorophenylboronic acid (230 mg, 1.48 mmol), copper acetate monohydrate (1.4 g, 7.2 mmol), and triethylamine (0.48 g, 4.8 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain compound 152 (1.99 g, 3.84 mmol). Yield 80%. Ms: 518 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.88(d,J=1.9Hz,1H),7.70(d,J=8.8Hz,1H),7.38-7.25(m,3H) ,6.99(d,J=8.9Hz,1H),5.74(d,J=4.7Hz,1H),4.33(d,J=11.9Hz,1H),3.38(d,J=10.8Hz ,1H),3.31(s,1H),3.27(s,3H),2.57-2.52(m,1H),2.35(d,J=11.6Hz,1H),2.19(d,J=1 2.1Hz, 1H), 2.15-1.90 (m, 5H), 1.78 (s, 2H), 1.36 (dd, J=24.1, 13.1Hz, 2H), 1.10 (s, 1H).

[0426] Example 153 Synthesis of compound 5-bromo-2-((S)-1-(3,4-difluorophenyl)piperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazole (153) TIFF0007591566000259.tif3777

[0427] 152 (52 mg, 0.1 mmol) was dissolved in THF (1 mL), and a solution of dimethylsulfide borane in tetrahydrofuran (2 M, 0.08 mL, 0.15 mmol) was added dropwise at room temperature while stirring. After stirring for 2 hours, acetone and a small amount of dilute hydrochloric acid were added, the mixture was dried by rotation, and 153 (37 mg, 0.073 mmol) was obtained by column chromatography. Yield: 73%. Ms: 504 (M+H + ), 1 H NMR(400MHz,d6-DMSO)δ7.77(d,J=1.7Hz,1H),7.68(d,J=8.7Hz,1H),7.25(dd,J=8.7,1.8Hz ,1H),7.19(dd,J=19.7,9.6Hz,1H),7.09(ddd,J=14.5,6.9,2.7Hz,1H),6.77(d,J=9.0Hz,1H ),5.46(s,1H),4.49(t,J=12.1Hz,1H),3.47-3.37(m,2H),3.25(s,3H),2.30-2.14(m,2H),2 .14-2.03(m,2H),1.94(d,J=23.2Hz,3H),1.62(dd,J=37.1,12.3Hz,5H),1.30-1.11(m,3H).

[0428] Example 154 Synthesis of compound (S)-6-(5-amino-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one (154) TIFF0007591566000260.tif4294

[0429] 152 (518 mg, 1 mmol) was dissolved in DMSO (5 mL), and ammonia water (1 mL), DMA (17 mg, 0.2 mmol), and CuI (19 mg, 0.1 mmol) were added. The mixture was protected with nitrogen gas and heated and stirred at 100°C overnight. After the reaction was completed and cooled, the mixture was poured into water (25 mL) and extracted with ethyl acetate (5 mL x 3). The organic phases were combined, washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, and rotary dried to obtain 154 (222 mg, 0.49 mmol). Yield: 49%. Ms: 455 (M+H + ).

[0430] Example 155 Synthesis of compound (S)-1-(3,4-difluorophenyl)-6-(1-((trans)-4-methoxycyclohexyl)-5-(3-methyl-2-oxoimidazolidin-1-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (155) Synthesis of 1-(2-chloroethyl)-3-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)urea (155-1) TIFF0007591566000261.tif3693

[0431] 154 (454 mg, 1 mmol) and DMAP (12 mg, 0.1 mmol) were added to THF (5 mL). 2-Chloroethyl isocyanate (105 mg, 1 mmol) was added in several portions, and the mixture was stirred at room temperature for 2 hours after the addition. Water was added and the mixture was extracted with ethyl acetate to obtain 155-1 (450 mg, 0.8 mmol). Yield: 80%.

[0432] Synthesis of (S)-1-(3,4-difluorophenyl)-6-(1-((trans)-4-methoxycyclohexyl)-5-(3-methyl-2-oxoimidazolidin-1-yl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (155) TIFF0007591566000262.tif4084

[0433] 155-1 (450 mg, 0.8 mmol) was dissolved in THF (5 mL), NaH (96 mg, 2.4 mmol) was added at room temperature, and the mixture was stirred for 2 hours. After that, iodomethane (227 mg, 1.6 mmol) was added and stirring was continued for another hour. Water (15 mL) was poured in, and the mixture was extracted with DCM (5 mL x 3). 155 (257 mg, 0.48 mmol) was obtained by column chromatography. Yield: 60%. Ms: 538 (M+H + ).

[0434] Example 156 Synthesis of compound (E)-3-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-N,N-dimethylacrylamide (156): TIFF0007591566000263.tif34113

[0435] Compound 152 (100 mg, 0.19 mmol), N,N-dimethylacrylamide (128 mg, 1 mmol), palladium acetate (2 mg, 0.009 mmol), triphenylphosphine (3 mg, 0.011 mmol), and triethylamine (100 mg, 1 mmol) were added to a sealed tube, heated to 130° C., and maintained at 130° C. overnight. After cooling, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and subjected to column chromatography to obtain 100 mg of a solid (compound 156). Yield: 96%. Ms: 537 (M+H + ) was obtained.

[0436] Example 157 Synthesis of compound (S)-1-(3,4-difluorophenyl)-6-(1-(((trans)-4-methoxycyclohexyl)-5-vinyl-1H-benzo[d]imidazol-2-yl)piperidin-2-one (Compound 157): TIFF0007591566000264.tif41116

[0437] Compound 152 (50 mg, 0.1 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (20 mg, 0.2 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (8 mg, 0.01 mmol), and potassium carbonate (30 mg, 0.2 mmol) were dissolved in 5 mL of dioxane, purged with nitrogen gas three times, and stirred at 100 °C for 10 hours. After cooling, the mixture was extracted three times with ethyl acetate, and the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 30 mg of a solid (compound 157). Yield 67%. Ms: 466 (M + H + ), 1 H NMR(400MHz,d6-DMSO)δ7.88(d,J=1.9Hz,1H),7.70(d,J=8.8Hz,1H),7.38-7.22(m,3H),6. 99(d,J=8.9Hz,1H),6.62(dd,J=16.8Hz,10.0Hz,1H),5.74(d,J=4.7Hz,1H),5.61(dd,J=16 .8Hz,2.1Hz,1H),5.20(dd,J=10.0Hz,2.1Hz,1H),4.33(d,J=11.9Hz,1H),3.40-3.35(m,1H) ),3.27(s,3H),2.62-2.53(m,2H),2.27-1.78(m,9H),1.45-1.24(m,2H),1.22-1.02(m,1H).

[0438] Example 158 Synthesis of compound 5-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one (158) TIFF0007591566000265.tif39111

[0439] 152 (518 mg, 1 mmol) was dissolved in dioxane, and one drop of water was added. Pd(dppf)Cl2 (73 mg, 0.1 mmol), potassium carbonate (276 mg, 2 mmol) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (747 mg, 3 mmol) were added. The mixture was stirred at 100° C. overnight, and compound 158 (291 mg, 0.52 mmol) was obtained by column chromatography. Yield: 52%. Ms: 561 (M+H + ). 1 H NMR(400MHz,d6-DMSO)δ7.99(d,J=2.2Hz,1H),7.89(d,J=1.5Hz,1H),7.80(s,1H),7.70(d,J=8.7Hz,1H),7.3 3(dd,J=18.7,8.8Hz,3H),7.02(d,J=8.8Hz,1H),5.73(s,1H),4.33(s,1H),3.52(s,3H),3.47(s,1H),3.43-3. 37(m,1H),3.28(s,3H),2.55(d,J=6.7Hz,1H),2.35(d,J=13.6Hz,1H),2.25(d,J=12.7Hz,1H),2.12(s,1H),2. 09(s,3H),2.03(d,J=12.6Hz,3H),1.79(s,2H),1.37(dd,J=22.4,11.5Hz,2H),1.21(dd,J=27.8,12.2Hz,2H).

[0440] Example 159 Synthesis of compound (S)-1-(3,4-difluorophenyl)-6-(1-((trans)-4-methoxycyclohexyl)-5-(methyl(piperidin-4-yl)amine)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (159) Synthesis of 4-((2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)amino)piperidine-1-carboxylic acid tert-butyl ester (159-1) TIFF0007591566000266.tif41115

[0441] 154 (50 mg, 0.11 mmol), 4-Boc-piperidone (66 mg, 0.33 mmol), and acetic acid (6.6 mg, 0.11 mmol) were added to DCE (1 mL), and sodium triacetoxyborohydride (93 mg, 0.44 mmol) was added in several portions while stirring at room temperature. After the addition, the mixture was stirred at room temperature for 30 min, and then rotary dried and subjected to column chromatography to obtain 159-1 (56 mg, 0.09 mmol). Yield: 82%.

[0442] Synthesis of 4-((2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester (159-2) TIFF0007591566000267.tif40108

[0443] 159-1 (50 mg, 0.08 mmol) was added to THF (0.5 mL), and NaH (6.3 mg, 0.16 mmol) was added under ice-water bath, and the mixture was stirred for 10 minutes. Iodomethane (34 mg, 0.24 mmol) was added, and the mixture was stirred for 6 hours. Ice water (6 mL) was added, and the mixture was extracted with dichloromethane, and 159-2 (37 mg, 0.056 mmol) was obtained by column chromatography. Yield: 71%.

[0444] Synthesis of compound (S)-1-(3,4-difluorophenyl)-6-(1-((trans)-4-methoxycyclohexyl)-5-(methyl(piperidin-4-yl)amine)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (159) TIFF0007591566000268.tif38108

[0445] 159-2 (37 mg, 0.056 mmol) was added to DCM (1 mL), TFA (0.25 mL) was added, stirred at room temperature for 6 h, rotary evaporated, pH was adjusted to 8-9 with saturated sodium bicarbonate, and extracted with DCM to give 159 (25 mg, 0.046 mmol). Yield: 82%. Ms: 552 (M+H + ).

[0446] Example 160 Synthesis of compound ethyl 2-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)acetic acid ethyl ester (160) TIFF0007591566000269.tif41111

[0447] 152 (52 mg, 0.1 mmol) was dissolved in mesitylene, and Pd(dppf)Cl2 (7 mg, 0.01 mmol), BINAP (6 mg, 0.01 mmol), DMAP (12 mg, 0.1 mmol) and monoethyl malonate potassium salt (17 mg, 0.1 mmol) were added. The mixture was stirred at 140 °C for 24 h, and 160 (10 mg, 0.02 mmol) was obtained by column chromatography. Yield: 20%. Ms: 526 (M+H + ).

[0448] Example 161 Synthesis of compound (tert-butyl (E)-3-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)acrylate (161): TIFF0007591566000270.tif35125

[0449] Compound 152 (100 mg, 0.19 mmol), acrylic acid tert-butyl ester (128 mg, 1 mmol), palladium acetate (2 mg, 0.009 mmol), triphenylphosphine (3 mg, 0.011 mmol), and triethylamine (100 mg, 1 mmol) were added to a sealed tube, heated to 130° C., and maintained at 130° C. overnight. After cooling, water was added, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and subjected to column chromatography to obtain 100 mg of a solid (compound 161). Yield: 96%. Ms: 566 (M+H + ).

[0450] Example 162 Synthesis of compound 5-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1-methylpyridin-2(1H)-one (162) TIFF0007591566000271.tif40115

[0451] 152 (518 mg, 1 mmol) was dissolved in dioxane, and one drop of water was added. Pd(dppf)Cl2 (73 mg, 0.1 mmol), potassium carbonate (276 mg, 2 mmol) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one (747 mg, 3 mmol) were added. The mixture was stirred at 100° C. overnight, and compound 162 (291 mg, 0.52 mmol) was obtained by column chromatography. Yield 52%. Ms: 547 (M+H + ). 1H NMR(400MHz,d6-DMSO)δ8.13(s,1H),7.92-7.82(m,2H),7.72(d,J=8.5Hz,1H),7.33(dd,J= 18.2,9.1Hz,3H),7.03(s,1H),6.47(d,J=9.3Hz,1H),5.75(d,J=9.8Hz,1H),4.33(s,1H),3 .51(s,3H),3.43(d,J=25.9Hz,1H),3.28(s,3H),2.56(s,1H),2.37(s,1H),2.31-2.19(m,1 H),2.13(s,2H),2.04(d,J=10.6Hz,3H),1.79(s,2H),1.45-1.31(m,2H),1.23-1.10(m,2H).

[0452] Example 163 Synthesis of compound 2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazole-5-carbonitrile (163) TIFF0007591566000272.tif3797

[0453] (518 mg, 1 mmol) was dissolved in NMP (5 mL), and further cuprous cyanide (179 mg, 2 mmol), cuprous iodide (19 mg, 0.1 mmol) and 8-hydroxyquinoline (28 mg, 0.2 mmol) were added and stirred at 100° C. overnight. It was poured into water (25 mL), extracted with ethyl acetate, spun dry, and purified by column chromatography to give 163 (52 mg, 0.11 mmol). Yield: 11%. Ms: 465 (M+H + ).

[0454] Example 164 Synthesis of compound 6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one (164) N-(5-bromo-2-(((trans)-4-methoxycyclohexyl)amine)phenyl)-6-oxopiperidine-2-formamide (164-1) TIFF0007591566000273.tif40101

[0455] Intermediate 2 (2.98 g, 10 mmol) was dissolved in dichloromethane (30 mL), and 2-piperidone-6-carboxylic acid (1.43 g, 10 mmol), propylphosphonic anhydride (50% in EA, 6.36 g, 10 mmol) and DIEA (1.54 g, 12 mmol) were added. After the addition was completed, the mixture was stirred at room temperature overnight, rotovapped and subjected to column chromatography to obtain 164-1 (3.4 g, 8 mmol). Yield 80%.

[0456] Synthesis of 6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)piperidin-2-one (164-2) TIFF0007591566000274.tif4496

[0457] 164-1 (3.4 g, 8 mmol) was added to acetic acid (30 mL), stirred at 50° C. for 3 days, rotary evaporated, dissolved in dichloromethane, washed with saturated sodium bicarbonate solution, and dried over anhydrous sodium sulfate. Rotary evaporated and purified by column chromatography to give 164-2 (1.95 g, 4.8 mmol). Yield 60%.

[0458] Synthesis of 6-(5-bromo-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorophenyl)piperidin-2-one (164) TIFF0007591566000275.tif41113

[0459] 164-2 (1.95 g, 4.8 mmol), 3,4-difluorophenylboronic acid (230 mg, 1.48 mmol), copper acetate monohydrate (1.4 g, 7.2 mmol), and triethylamine (0.48 g, 4.8 mmol) were dissolved in acetonitrile (20 mL) and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with hydrochloric acid (1N), extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain compound 164 (1.99 g, 3.84 mmol). Yield 80%. Ms: 518 (M+H + ).

[0460] Example 165 Synthesis of (S)-6-(5-((1-acetylpiperidin-4-yl)(methyl)amine)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1-(3,4-difluorobenzene)piperidin-2-one (Compound 165) TIFF0007591566000276.tif36104

[0461] Compound 159 (551 mg, 1 mmol) and triethylamine (303 mg, 3 mmol) were dissolved in 20 mL of DCM, and acetyl chloride (120 mg, 1.5 mmol) was slowly added dropwise under ice-water bath conditions, and the mixture was allowed to react for 3 hours. The mixture was poured into water, extracted with dichloromethane, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 415 mg of the product (compound 165). Yield 70%. Ms: 594 (M+H + ).

[0462] Example 166 Synthesis of compound N-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)methanesulfonamide (166) TIFF0007591566000277.tif46114

[0463] 154 (20 mg, 0.04 mmol) was dissolved in DCM (0.5 mL), methanesulfonic anhydride (8 mg, 0.04 mmol) was added, and the mixture was stirred at room temperature for 1 h. Rotational drying and column chromatography gave 166 (5 mg, 0.009 mmol). Yield: 23%. Ms: 533 (M+H + ).

[0464] Example 167 Synthesis of compound N-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)trifluoromethanesulfonamide (167) TIFF0007591566000278.tif41120

[0465] 154 (20 mg, 0.04 mmol) was dissolved in DCM (0.5 mL), trifluoromethanesulfonic anhydride (11 mg, 0.04 mmol) was added, and the mixture was stirred at room temperature for 1 h. Rotational drying and column chromatography gave 166 (5 mg, 0.008 mmol). Yield: 21%. Ms: 587 (M+H + ).

[0466] Example 168 Synthesis of compound 1-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-3-methylurea (168) TIFF0007591566000279.tif56144

[0467] 154 (20 mg, 0.04 mmol) was dissolved in THF (0.5 mL), TEA (8 mg, 0.08 mmol) was added, and the mixture was cooled to 0°C in an ice-water bath. Triphosgene (5 mg, 0.016 mmol) was added, and the mixture was stirred for 30 minutes. Methylamine hydrochloride (3 mg, 0.04 mmol) was added, and the mixture was allowed to warm to room temperature and stirred for 30 minutes. Column chromatography was used to obtain 168 (15 mg, 0.03 mmol). Yield: 73%. Ms: 512 (M+H+ ).

[0468] Example 169 Synthesis of compound N-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)acetamide (169) TIFF0007591566000280.tif53118

[0469] 154 (20 mg, 0.04 mmol) was dissolved in DCM (0.5 mL), and acetyl chloride (3 mg, 0.04 mmol) was added dropwise at room temperature with stirring, and the mixture was stirred for 2 h. 169 (17 mg, 0.03 mmol) was obtained by column chromatography. Yield: 86%. Ms: 5497 (M+H + ).

[0470] Example 170 Synthesis of compound N-(2-((S)-1-(3,4-difluorophenyl)-6-oxopiperidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-2-(dimethylamino)acetamide (170) TIFF0007591566000281.tif50146

[0471] 154 (20 mg, 0.04 mmol) was dissolved in DMF (0.5 mL), N,N-dimethylglycine (4 mg, 0.04 mmol), HATU (15 mg, 0.04 mmol) and DIEA (5 mg, 0.04 mmol) were added, stirred at room temperature overnight, poured into water (3 mL), extracted with ethyl acetate and purified by column chromatography to give 170 (12 mg, 0.02 mmol). Yield: 50%. Ms: 540 (M+H + ).

[0472] Example 171 Synthesis of compound (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 171): Synthesis of trans-4-((4-bromo-2-nitrophenyl)amino)cyclohexanol (Intermediate 171-1): TIFF0007591566000282.tif40125

[0473] 4-Bromo-1-fluoro-2-nitrobenzene (2g, 9.14mmol), (trans)-4-aminocyclohexanol (1.26g, 10.97mmol) and potassium carbonate (2.6g, 18.84mmol) were dissolved in acetonitrile (30mL), heated to 80°C and stirred for 5 hours. After cooling, 100mL of water was added, filtered, washed with water, and the filter cake was subjected to column chromatography to obtain 2.4g of a solid (Intermediate 171-1). Yield 83.7%.

[0474] Synthesis of 4-bromo-N-((trans)-4-ethoxycyclohexyl)-2-nitroaniline (Intermediate 171-2): TIFF0007591566000283.tif39103

[0475] Intermediate 171-1 (2.4g, 7.65mmol) and sodium hydride (0.37g, 15.42mmol) were dissolved in 20mL of tetrahydrofuran, and iodoethane (2.4g, 15.39mmol) was added dropwise under ice bath and reacted overnight. Poured into ice water, extracted with ethyl acetate (30mL x 3), washed once with saturated saline (20mL), dried the organic phase with anhydrous sodium sulfate, concentrated, and obtained 1.5g of product (intermediate 171-2) by column chromatography. Yield 58%.

[0476] Synthesis of 4-bromo-N1-((trans)-4-ethoxycyclohexyl)benzene-1,2-diamine (Intermediate 171-3): TIFF0007591566000284.tif4490

[0477] Intermediate 171-2 (1.5g, 4.38mmol) and aqueous ammonia (3mL) were dissolved in 20mL of tetrahydrofuran and 5mL of water, sodium dithionite (3.8g, 21.83mmol) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated by standing, and the aqueous layer was extracted with ethyl acetate (30mLx2). The organic layers were combined, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 850mg of a solid (intermediate 171-3). Yield 62%.

[0478] Synthesis of 4-(3,5-dimethylisoxazol-4-yl)-N1-((trans)-4-ethoxycyclohexyl)benzene-1,2-diamine (Intermediate 171-4): TIFF0007591566000285.tif43119

[0479] Intermediate 171-3 (850 mg, 2.73 mmol), 3,5-dimethylisoxazole-4-boronic acid pinacol ester (923 mg, 4.12 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (10 mg, 0.014 mmol), potassium carbonate (753 mg, 5.44 mmol) were dissolved in 30 mL of dioxane and 50 mL of water, purged with nitrogen gas three times, and stirred at 100 ° C for 10 hours. After cooling, it was extracted three times with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 580 mg of a solid (intermediate 171-4). Yield 65%.

[0480] Synthesis of tert-butyl ((S)-3-((tert-butyldimethylsilyl)oxy)-1-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)propylcarbamate (Intermediate 171-5): TIFF0007591566000286.tif40113

[0481] Intermediate 10 (673 mg, 2.12 mmol) was dissolved in N,N-dimethylformamide (10 mL), and intermediate 171-4 (580 mg, 1.76 mmol) and sodium pyrosulfite (670 mg, 3.53 mmol) were added, and the mixture was reacted at 80 degrees for 5 hours. 50 mL of water was added, and the mixture was extracted with ethyl acetate (30 mL x 3), and the organic phases were combined, washed once with saturated saline (20 mL), dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 420 mg of the product (intermediate 171-5). Yield: 38.2%.

[0482] Synthesis of (S)-3-amino-3-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-ylpropan-1-ol (Intermediate 171-6): TIFF0007591566000287.tif40106

[0483] Intermediate 171-5 (420 mg, 0.67 mmol) and potassium hydrogen fluoride (262 mg, 3.35 mmol) were dissolved in methanol (20 mL), 5 mL of concentrated hydrochloric acid was added, and the mixture was reacted at 30 degrees overnight. The pH was adjusted to 9-10, concentrated, extracted with dichloromethane (30 mL x 4), dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 200 mg of the product (intermediate 171-6). Yield: 72.5%.

[0484] (S)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxadiazin-2-one (Intermediate 171-7) TIFF0007591566000288.tif43102

[0485] Intermediate 171-6 (200 mg, 0.48 mmol) and triethylamine (97 mg, 0.96 mmol) were dissolved in 60 mL of tetrahydrofuran, heated to 35° C., triphosgene (44 mg, 0.15 mmol) was added in several portions, and reacted for 30 minutes. The mixture was washed with water, washed with 1N hydrochloric acid, extracted with ethyl acetate, dried over anhydrous sodium sulfate, concentrated, and subjected to column chromatography to obtain 116 mg of the product (intermediate 171-7). Yield: 54.8%.

[0486] Synthesis of (S)-3-(3,4-difluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (compound 171): TIFF0007591566000289.tif3692

[0487] Intermediate 171-6 (60 mg, 0.14 mmol), 3,4-difluorophenylboronic acid (90 mg, 0.57 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg, 0.3 mmol) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 60 mg of the product (compound 171). Yield 77.9%. Ms: 551 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.81(d,J=8.5Hz,1H),7.73(d,J=1.3Hz,1H),7.46(ddd,J=11.9,7.4,2.4Hz,1H),7.37(dd,J=19. 6,9.1Hz,1H),7.16(dd,J=8.5,1.5Hz,1H),7.14-7.07(m,1H),5.82(s,1H),4.58(t,J=10.0Hz,1H),4.40-4.28(m,2H),3. 49(q,J=7.0Hz,3H),3.31(s,1H),2.68(t,J=13.0Hz,1H),2.40(s,3H),2.24(s,4H),2.21(d,J=3.3Hz,1H),2.17(d,J=3.0 Hz,1H),2.09(d,J=12.8Hz,1H),2.02(d,J=12.3Hz,1H),1.84(d,J=11.8Hz,1H),1.42-1.32(m,2H),1.12(t,J=7.0Hz,3H).

[0488] Example 172 Synthesis of compound (S)-3-(4-chloro-3-fluorophenyl)-4-(5-(3,5-dimethylisoxazol-4-yl)-1-((trans)-4-ethoxycyclohexyl)-1H-benzo[d]imidazol-2-yl)-1,3-oxazinean-2-one (Compound 172) TIFF0007591566000290.tif42106

[0489] Intermediate 171-6 (56 mg, 0.13 mmol), 4-chloro-3-fluorophenylboronic acid (90 mg, 0.52 mmol), copper acetate monohydrate (60 mg, 0.3 mmol), and triethylamine (30 mg, 0.3 mmol) were dissolved in 20 mL of acetonitrile and reacted at 30° C. overnight. The mixture was filtered, concentrated, washed with 1N hydrochloric acid, extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 58 mg of the product (compound 172). Yield 78.8%. Ms: 566 (M+H + ), 1H NMR(400MHz,d6-DMSO)δ7.82(d,J=8.5Hz,1H),7.72(d,J=1.3Hz,1H),7.53(t,J=8.6Hz,1H),7.46(dd,J=10.8,2.3Hz ,1H),7.26-7.06(m,2H),5.88(s,1H),4.56(dd,J=11.1,9.0Hz,1H),4.35(dd,J=7.1,3.6Hz,2H),3.49(q,J=6.9Hz,3 H),2.68(t,J=13.1Hz,1H),2.40(s,3H),2.25(d,J=16.9Hz,4H),2.21(s,1H),2.18(s,1H),2.10(d,J=11.8Hz,1H),2 .03(d,J=12.5Hz,1H),1.85(d,J=11.2Hz,1H),1.37(d,J=5.7Hz,2H),1.28(d,J=10.8Hz,1H),1.12(t,J=7.0Hz,3H).

[0490] The beneficial effects of the present invention will now be demonstrated by experimental examples.

[0491] Experimental Example 1: Detection of inhibitory activity of compounds against CBP / EP300 bromodomain (BRD) 1. Experimental Method A. Experimental Method AlphaScreen detection experiment of CBP and EP300 Preparation of 1.1x detection buffer

[0492] 2. Compound Preparation Compounds were first diluted 1000x the final concentration in the Precision autosampler (3-fold serial dilutions): 1) Using an Echo autosampler, 50 μL of compound at a stock concentration of 10 mM was transferred to well A2 of a 96-well plate. 2) Using Precision, 30 μL of DMSO was transferred to wells A1 and A3 to A12. 3) Using the Precision, transfer 15 μL from A2 to A3, then continue sequentially through A10 to A11 to complete the 1:3 serial dilution. 4) The compound plate was centrifuged for 1 minute at a rotation speed of 1000 rpm.

[0493] 3. Preparation of Detection Plate Using an Echo autosampler, 20 nL of each concentration was transferred from the compound plate to the detection plate: from placement plate A1 to detection plate A1 and A2, and from placement plate A2 to detection plate A3 and A4.

[0494] 4. Bromodomain (BRD) binding detection experiment 1) Preparation of 2x Protein and Polypeptide Solutions Proteins and polypeptides were dissolved in detection buffer at 1x concentration. 2) 10 μL of protein and polypeptide solution was transferred to each well of columns 3 to 24 of the detection plate, and 10 μL of 1x detection buffer was transferred to wells of columns 1 to 2 of the detection plate as a negative control. 3) The detection plate was centrifuged for 1 minute at a rotation speed of 1000 rpm. 4) Incubate at room temperature for 15 minutes. 5) The acceptor and donor beads were prepared in 2x acceptor and donor solutions with 1x detection buffer. 6) 2x acceptor and donor solutions were transferred to the detection plate. 15 μL of acceptor solution and donor solution were added and protected from light. 7) The detection plate was centrifuged at 1000 rpm for 1 minute and incubated at room temperature for 60 minutes.

[0495] 5. The endpoint was read in EnSpire and Alpha modes.

[0496] 6. Curve fitting The experimental data was entered into Excel, and the inhibition rate Inh% was obtained using equation (1). Equation (1): Inh%=(Max-Signal) / (Max-Min)×100 where Max:DMSO added control, Max:DMSO added low control, and the obtained data was entered into the XL-Fit software and the IC was calculated using equation (2). 50 The value of was obtained. Equation (2): Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×Hill Slope)

[0497] 2. Experimental Results [Table 1]

[0498] From the experimental results shown in Table 1, the compounds of the present invention have remarkable inhibitory activity against CBP BRD and EP300 BRD at the same time. In particular, compounds 117, 112, 113, 106, 143, 171, and 172 have IC 50 The IC value for EP300 BRD was as low as 5.0 nM or less. 50 It can be seen that the concentration is low, at 3.0 nM or less.

[0499] Experimental Example 2 Inhibitory effect of the compounds of the present invention on cell proliferation of prostate cancer CWR22RV1 1. Experimental Procedure (1) Prostate cancer CWR22RV1 cells were subcultured in cell culture medium, and cells in good growth condition were inoculated into a 96-well plate at 80 μL per well. The number of cells in each well was set to 1,500, and the cells were cultured overnight in a cell incubator at 37°C and 5% CO2. (2) Drugs were prepared in dimethyl sulfoxide (DMSO) at a stock concentration of 30 mM. Before use, they were further diluted 3-fold with DMSO, and then serially diluted 3-fold to obtain 9 concentrations. Each concentration of compound was further diluted 200-fold with culture medium (so that the DMSO concentration in the culture system was 0.1%), and two wells were prepared in duplicate for each concentration. 20 μL of the diluted compound was added to the cell culture wells (final concentrations were 10 μM, 3.3 μM, 1.1 μM, etc.) and gently shaken to mix uniformly. Separately, three negative control wells containing only cells and three blank control wells containing only culture medium were prepared (20 μL of DMSO diluted 200-fold with culture medium was added to each of the six wells).

[0500] 2. Finding Results (1) After culturing for 6 days, 10 μL of CCK-8 was added to each well, and the cells were further cultured for 2.5 hours in a cell incubator at 37°C and 5% CO2. (2) The absorbance (OD value) at 450 nm was measured using a multi-microplate reader. (3) The data were analyzed using the dose-response-inhibition equation in the software GraphPad Prism 6, and the IC 50 Got the value.

[0501] 3. Experimental Results IC of the compounds of the present invention inhibiting activity against CWR22RV1 cells 50 The results (nM) are shown in Table 2. A is IC 50 is 500nM or less, B is IC 50 is greater than 500nM and less than 2000nM, and C is IC 50 is greater than 2000 nM.

[0502] [Table 2]

[0503] The compounds of the present invention have a remarkable inhibitory effect on prostate cancer CWR22RV1 cells, and in particular, compounds 112, 113, and 117 have an IC 50 It can be seen that the concentration is low, at less than 500 nM.

[0504] Experimental Example 3: Inhibitory effect of the compounds of the present invention on cell proliferation of other tumors 1. Experimental Method In the same manner as in Experimental Example 2, CWR22RV1 cells were replaced with the tumor cells in Table 3, and the IC 50 The results are shown in Table 3.

[0505] 2. Experimental Results In Table 3, A is IC 50 is 500nM or less, B is IC 50 is greater than 500nM and less than 2000nM.

[0506] [Table 3]

[0507] It is found that the compound prepared by the present invention has a clear inhibitory effect on the proliferation of other prostate cancer cells, leukemia cells, breast cancer cells, and multiple myeloma cells, which indicates that the compound of the present invention exerts an inhibitory effect on various tumors at the same time.

[0508] Experimental Example 4: Inhibitory effect of the compound of the present invention in combination with the CDK4 / 6 inhibitor palbociclib on the proliferation of prostate cancer CWR22RV1 cells 1. Experimental Procedure IC of the compounds of the present invention, palbociclib, and combinations of the compounds of the present invention and palbociclib against CWR22RV1 cells 50 (nM) was measured and calculated. The specific procedure is as follows.

[0509] 1) CWR22RV1 cells were subcultured in cell culture medium, and cells in good growth condition were inoculated into a 96-well plate, with 60 μL per well and 2,000 cells per well, and cultured overnight in a cell incubator at 37°C and 5% CO2.

[0510] 2) Drugs were prepared in dimethyl sulfoxide (DMSO) at 10 mM stock solution. Before use, they were further diluted 3-fold with DMSO and further serially diluted 3-fold to obtain 9 concentrations. Each concentration of compound was further diluted 200-fold with culture medium (so that the DMSO concentration in the culture system was 0.1%), and two wells were made in duplicate for each concentration. 20 μL of diluted compound was added to cell culture wells (final concentrations were 10 μM, 3.3 μM, 1.1 μM…). Palbociclib was diluted to 500 nM, 150 nM, 50 nM, and 5 nM with culture medium, respectively, and 20 μL of diluted compound was added to the corresponding cell culture wells (final concentrations were 100 nM, 30 nM, 10 nM, and 1 nM) and mixed evenly by gentle shaking. Separately, three negative control wells to which only cells were added and three blank control wells to which only culture medium was added (20 μL of DMSO diluted 200-fold with culture medium was added to each of the six wells) were prepared.

[0511] 2. Finding Results 1) After culturing for 6 days, 10 μL of CCK-8 was added to each well, and the cells were further cultured for 2.5 hours in a cell incubator at 37°C and 5% CO2. 2) The absorbance (OD value) at 450 nm was measured using a multi-microplate reader. 3) The data were analyzed using the dose-response-inhibition equation in the software GraphPad Prism6 to obtain IC 50 Got the value.

[0512] 3. Experimental Results IC of inhibitory activity against CWR22RV1 cells by combination of compounds of the present invention with palbociclib 50 The results (nM) are shown in Table 4.

[0513] [Table 4]

[0514] When compound 172 was used alone, its IC 50 The IC50 value for palbociclib alone was 1500 nM, indicating that palbociclib alone had an IC50 value for CWR22RV1 cell activity. 50 The IC50 of compound 172 for CWR22RV1 cell activity was 100 nM, whereas when compound 172 was combined with palbociclib, the IC50 of compound 172 for CWR22RV1 cell activity was 100 nM. 50 Compound 172 in combination with 100-300 nM palbociclib significantly reduced the IC 50 was reduced to below 1 nM.

[0515] Experiments have shown that the combination of compound 172 of the present invention and palbociclib exerts a synergistic inhibitory effect in inhibiting the activity of prostate cancer CWR22RV1 cells.

[0516] Experimental Example 5: Inhibitory effect of the compound of the present invention in combination with the CDK4 / 6 inhibitor palbociclib on the proliferation of breast cancer MCF-7 cells 1. Experimental Method In the same manner as in Experimental Example 4, CWR22RV1 cells were replaced with MCF-7 cells, and the IC of the compound of the present invention, palbociclib, and the combined use of the compound of the present invention and palbociclib against MCF-7 cells was measured. 50 (nM) was measured and the calculated results are shown in Table 5.

[0517] 2. Experimental Results [Table 5]

[0518] Compound 172 alone had an IC 50The IC50 value for palbociclib alone was 72 nM, indicating that palbociclib alone had an IC50 value for MCF-7 cell activity. 50 The IC50 value for compound 172 activity in MCF-7 cells was 12,800 nM, but when compound 172 was combined with palbociclib, the IC50 value for compound 172 activity in MCF-7 cells was 12,800 nM. 50 Compound 172 in combination with 100-300 nM palbociclib significantly reduced the IC 50 was reduced to below 10 nM.

[0519] Experiments have shown that the combination of compound 172 of the present invention with palbociclib exerts a synergistic inhibitory effect in inhibiting the activity of breast cancer MCF-7 cells.

[0520] As described above, the present invention provides a novel compound that has high selectivity for EP300 / CBP and can effectively inhibit the activity of EP300 / CBP. Furthermore, the compound of the present invention has excellent inhibitory effects on various tumor cells, including prostate cancer cells, leukemia cells, breast cancer cells and multiple myeloma cells. Therefore, the compound of the present invention has potential applications in the manufacture of EP300 / CBP inhibitors and drugs for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem / progenitor cells, and regulating regulatory T cells.

Claims

1. A compound of formula I, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, Here, R 1 is 0 to 4 R 7 a 5-6 membered saturated or unsaturated cycloalkyl group substituted with 0 to 4 R 7 R is selected from 5-6 membered saturated or unsaturated heterocyclyl groups substituted with 7 are each independently 1~5 Alkyl group or its deuterated derivative, =O, C 1~5 is selected from an alkoxy group or its deuterated derivative, a halogen, a hydroxy group, and a cyano group; R 2 is 0 to 4 R 5 a 5- to 6-membered saturated cycloalkyl group substituted with 0 to 4 R 5 R is selected from 5-6 membered saturated heterocyclyl groups substituted with 5 are each independently 1~5 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, =O, C 1~5 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, cyano groups, is selected from R 6 is C 1~5 is an alkyl group, R 3 teeth, where R 4 is selected from and R 9 is selected from an alkyl group or a haloalkyl group; or a deuterated form thereof; or a salt thereof; or a conformer thereof; or a crystalline form thereof; or a solvate thereof.

2. 2. A compound according to claim 1, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, comprising: 1 is 1 to 3 R 7 a 5- to 6-membered saturated or unsaturated cycloalkyl group substituted with 1 to 3 R 7 wherein the heteroatoms on said heterocyclyl group are selected from O, N, and S; 7 are each independently 1~3 is selected from an alkyl group or its deuterated form, =O; R 2 is 1 to 3 R 5 a 5- to 6-membered saturated cycloalkyl group substituted with 1 to 3 R 5 wherein the heteroatoms on said heterocyclyl group are selected from O, N, and S; and R 5 are each independently 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, =O, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, cyano groups, is selected from R 6 is C 1~3 is alkyl, R 3 A compound, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, characterized in that:

3. A compound according to claim 1 or 2, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, wherein the structure of the compound is as shown in formula II-1: R 5 is C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 selected from an alkoxy group or its deuterated derivative, a halogen, and a hydroxy group, m being 1 or 2; R 1 , R 3 is as defined in claim 1, Or, the structure of the compound is as shown in Formula II-2: R 5 is C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, is selected from R 6 is C 1~3 is an alkyl group, R 1 , R 3 is as defined in claim 1, Or, the structure of the compound is as shown in Formula II-3: R 5 is C 1~3 Alkyl group or its deuterated derivative, C 1~5 Haloalkyl group, C 1~3 Alkoxy groups or their deuterated derivatives, halogens, hydroxy groups, is selected from R 6 is C 1~3 is an alkyl group, R 1 , R 3 is as claimed in claim 1 or 2, Or, the structure of the compound is as shown in Formula II-4: R 1 , R 3 A compound, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, characterized in that:

4. 4. A compound according to claim 3, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, comprising: 1 teeth is selected from And / or R 3 A compound, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, characterized in that:

5. A compound according to any one of the following, or a deuterated form thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof:

6. A compound represented by formula III-3, or a deuterated product thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, Here, R 1a , R 1b each independently represents hydrogen, deuterium, deuterated or non-deuterated C 1~3 Alkyl groups, deuterated or non-deuterated C 1~3 alkoxy groups, R x is hydrogen, deuterium, deuterated or non-deuterated C 1~2 Alkyl groups, deuterated or non-deuterated C 1~2 alkoxy groups, n 3 is 2 or 3, A compound, or a deuterated product thereof, or a salt thereof, or a conformer thereof, or a crystal form thereof, or a solvate thereof, characterized in that R3a is a halogen.

7. A compound according to any one of the following, or a deuterated form thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof:

8. Use of a compound according to any one of claims 1 to 7, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystalline form thereof, or a solvate thereof, in the manufacture of an EP300 inhibitor, a CBP inhibitor, or an EP300 / CBP inhibitor.

9. The EP300 / CBP inhibitor is a drug for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem / progenitor cells, and regulating regulatory T cells; the tumor is selected from hematological malignancies, gastric cancer, intestinal cancer, cervical cancer, bladder cancer, laryngeal cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma, or multiple myeloma, and the malignant disease of myeloid hematopoietic stem / progenitor cells is leukemia; The use according to claim 8, characterized in that the lymphoma is non-Hodgkin's lymphoma, diffuse large B-cell lymphoma and the leukemia is acute myeloid leukemia.

10. A drug for treating a disease, characterized in that it is a formulation produced by adding a pharmaceutically acceptable auxiliary material to a compound according to any one of claims 1 to 7, or a deuterated form thereof, or a salt thereof, or a conformational isomer thereof, or a crystal form thereof, or a solvate thereof, as an active ingredient.

11. A combination drug comprising a compound according to any one of claims 1 to 7, or a deuterated form thereof, or a salt thereof, or a conformer thereof, or a crystal form thereof, or a solvate thereof, used in simultaneous or separate administration in unit dosage forms of the same or different specifications, and another drug having an antitumor effect, and a pharma- ceutically acceptable carrier.

12. The combination drug according to claim 11, wherein the other drug having an antitumor effect is a chemotherapy drug or a radiotherapy drug, and the chemotherapy drug is a targeted drug.

13. The combination drug according to claim 11, wherein the other drug having an antitumor effect is one or more selected from a CDK4 / 6 inhibitor, a PARP inhibitor, an androgen receptor inhibitor, and an immune checkpoint inhibitor, and the CDK4 / 6 inhibitor is palbociclib.

Citation Information

Patent Citations

  • Benzofuran and Benzothiophene Derivatives Useful in Treating Hyperproliferative Disorders

    JP2006507215A

  • Novel benzimidazole dihydrothiadiazione derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions containing them.

    JP2011503016A

  • isoxazolyl-substituted imidazopyridines

    JP2018517672A

  • isoxazolyl-substituted benzimidazoles

    JP2018519249A

  • Fused heterocyclic compound having Anti-hcv effect

    WO2005121132A1